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ABSTRACT
AN ANAYLSIS OF ACCELERATED ATHEROSCLEROSIS IN THE 
HYPERGLYCEMIC HYPERLIPIDEMIC SYRIAN FiB HAMSTER
By
Adele Jeanne Marone 
University of New Hampshire, May, 2007 
Humans with diabetes mellitus are two to five times more likely to develop 
cardiovascular disease and do so at a much younger age than non-diabetics. This study 
utilized the Syrian FiB hamster, a model of human atherosclerosis, to: 1. determine 
whether one intraperitoneal injection of streptozotocin (STZ) could induce a diabetic-like 
hyperglycemic state, 2. compare the development of atherosclerotic lesions between non­
treated (N), hyperglycemic (G), hyperlipidemic (L) and combined 
hyperlipidemic/hyperglycemic (L+G) hamsters, and 3. determine whether lesion 
development was accelerated due to plasma levels of glucose, triglycerides, total 
cholesterol, non-HDL-C, HDL-C, or lipid hydroperoxides, or by the TC/HDL-C or 
TG/HDL-C ratio or the expression of MDA or LOX-1 in the vascular wall of the hamster 
aortic arch. Plasma, and aortic arch and pancreatic tissue were collected and analyzed at 
10 and 20 weeks.
Hamsters receiving one intraperitoneal injection of 40 mg/kg body weight 
of STZ had significantly elevated glucose levels compared to non-STZ injected hamsters. 
They also exhibited another characteristic of human diabetes, the atherogenic lipid triad 
characterized by hypertriglyceridemia, increased small dense LDL, and by week 20
x
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decreased HDL-C levels. The lack of dependence on insulin, and its apparent continued 
secretion from the beta cells in the STZ treated hamsters appears to be reflective of 
human type II diabetes with the L+G hamster exhibiting the conditions of both insulin 
resistance and insulin impairment. The L+G hamsters also exhibited extremely 
accelerated atherosclerosis while the G only hamster exhibited no lesion development. 
Hyperglycemia and lipidemia alone independently induced MDA and LOX-1 expression. 
The combination of hyperglycemia/hyperlipidemia could potentially increase the 
expression of MDA and LOX-1 requiring further investigation to quantitate these levels. 
Atherogenesis appeared to be mainly associated with increased TC and non-HDL-C. 
While hyperglycemia alone does not appear to induce atherogenesis it may contribute to 
the acceleration of atherosclerosis when combined with elevated numbers of small dense 
LDL particles, with oxidation a major contributing factor to the formation of such 
particles. Our findings suggest that the L+G Syrian FiB hamster is a useful model for 
determining the mechanism(s) involved in the development of accelerated atherosclerosis 
under the conditions of hyperglycemia.
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INTRODUCTION
Cardiovascular disease (CVD) has been the primary cause of death in the 
United States (US) every year except one since 1900. CVD claims more lives in the 
US each year than the next five leading causes of death combined. In 2003 the next 
five leading causes of death were cancer, chronic lower respiratory diseases, 
accidents, diabetes mellitus, and influenza/pneumonia [1, 2]. Nearly 2,600 
Americans die of CVD each day which averages approximately 1 death every 34 
seconds and in 2001 CVD accounted for 38.5% of all deaths in the US.
According to a Center for Disease Control and National Center for Health 
statistics report, if all forms of CVD were eliminated, life expectancy would increase 
by almost 7 years. If all forms of cancer were eliminated, life expectancy would 
increase by only 3 years. According to the same study, the probability at birth of 
eventually dying from CVD is 47%. The statistics for other causes of death are: 
cancer -  22%, accidents -  3%, diabetes -  2 % and human immunodeficiency virus 
(HIV) - 0.7 % [1, 2]. These statistics demonstrate just how dominant CVD is as a 
cause of death in the US.
Based on 2003 population data, the average life expectancy of people bom in 
the United States is now 77.5 years [2]. Recent declines in US death rates from CVD, 
due to new pharmaceuticals such as the statin drugs, and new surgical techniques, are 
largely responsible for the recent improvement in life expectancy. In the US, except 
for a relatively small increase in 1993, mortality from heart disease has steadily
1
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declined since 1980 [1]. Even so, CVD is predicted to be the main cause of death not 
only in developed countries but worldwide by the year 2020. There are two major 
reasons for this. The first is the rapidly increasing prevalence of CVD in developing 
countries where there has been a decline in the communicable diseases that were 
previously the predominant cause of death. These countries are also beginning to 
adopt Western habits such as high fat diets and more sedentary lifestyles, both of 
which are major risk factors for CVD. The second and more underlying cause is the 
increasing prevalence of two other risk factors, obesity and its associated type II 
diabetes, particularly in the United States [3-12].
Atherosclerosis is the primary cause of CVD resulting in many deaths from 
heart attack and stroke. Many Americans already have atherosclerotic lesion 
formation by their early teens [13] as indicated by the presence of early 
atherosclerotic lesions in the coronary arteries of 50% of Americans between 10 and 
14 years of age [14]. Atherosclerosis accounts for nearly three-fourths of all deaths 
from CVD. Therefore it can be stated that atherosclerosis alone is the leading cause 
of age-related morbidity and mortality in the Western world [15].
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CHAPTER I
ATHEROSCLEROTIC LESION DEVELOPMENT
Atherosclerosis is a highly characteristic pathological response in specific 
arteries and at specific sites within those arteries. In humans, lesions occur most 
often in the abdominal aorta but also occur in the coronary and carotid arteries, in 
the arch and descending thoracic aorta, and in arteries in the legs. Lesions form in 
arteries that are generally larger than 2 mm, except in diabetics where lesions often 
may also form in smaller peripheral arteries. Areas of turbulent flow or low shear 
stress that tend to occur at arterial branch points are more prone to a thickening of 
the intima with age. Intimal thickenings in these areas may contain smooth muscle 
cells of both the contractile and the synthetic phenotype. Atherosclerosis is most 
likely to develop at these intimal thickenings and they are therefore called lesion 
prone areas. While lesion development is a continuous process of varying degrees 
it is generally characterized as having three distinct stages: early, intermediate and 
advanced.
Early Stage - Fatty Streak Lesions
The early stage lesion is called the fatty streak and as its name implies it is 
characterized by the deposition lipid in the arterial intima. These lipids are mainly 
cholesterol esters derived from circulating lipoproteins, particularly low density 
lipoprotein (LDL). Some factors that most likely contribute to this lipid
3
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accumulation include (1) an increased plasma concentration of lipoproteins, 
especially LDL (2) endothelial dysfunction resulting in an increase in permeability 
allowing more of the smaller lipoproteins such as small, dense LDL particles to 
enter into the subendothelial space (3) aggregation of these particles due to 
interactions with extracellular matrix proteins and (4) entrapment of these particles 
due to a change in their physical characteristics such as an increased net negative 
charge.
In addition to intra- and extra-cellular lipid accumulation, monocyte 
infiltration is also a major characteristic of early stage lesion development. The 
adhesion of leukocytes to the endothelium in areas of increased permeability has 
been identified as one of the earliest events in atherogenesis [16]. There are three 
major groups of cellular adhesion molecules: the selectins, the immunoglobulin 
superfamily, and the integrins. All three of these adhesion molecule groups are 
involved in the multi-step process of monocyte migration and extravasation across 
the endothelium [17, 18]. These adhesion molecules are present on both endothelial 
cells (ECs) and leukocytes and each has a very specific role in one of the steps in 
this process.
The first step is the margination and rolling of monocytes in response to some 
insult or injury to the ECs. Selectins on both monocytes and ECs interact to form a 
weak, reversible bond causing the monocytes to slow and roll over the endothelium 
[19, 20]. Selectin expression may be induced by the cytokines interleukin-1 (IL-1), 
tumor necrosis factor alpha (TNF-a) and bacterial endotoxin.
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The next step is the firm adhesion of monocytes to ECs. The immunoglobulin 
superfamily adhesion molecules expressed on ECs responsible for this interaction 
are intercellular adhesion molecule-1 (ICAM-1) and vascular cellular adhesion 
molecule-1 (VCAM-1). The monocytes spread and then firmly adhere via binding 
of integrins on their surface, including very late antigen-4 (VLA-4) and lymphocyte 
function-associated antigen-1 (LFA-1) to VCAM-1 and ICAM-1 respectively on the 
ECs. ICAM-1 is constitutively expressed on ECs, but its expression can be 
increased by exposure to IL-1, interferon gamma (INF-y), TNF-a, and bacterial 
endotoxin. VCAM-1 is upregulated by IL-1, TNF, bacterial endotoxin, and 
interleukin 4 (IL-4). While VCAM-1 expression on ECs is lower than ICAM-1 
expression, VCAM-1 is the adhesion molecule most implicated in the pathogenesis 
of human atherosclerosis [21]. Data also suggests that the engagement of ICAM-1 
and VCAM-1 induces intracellular signaling in the ECs which results in the 
opening of the endothelial cell-to-cell junctions. Engagement of ICAM-1 and 
VCAM-1 also induces reactive oxygen species (ROS) production in ECs [22, 23]. 
ROS may also interfere with endothelial integrity by oxidizing cysteine residues in 
tyrosine phosphatases which then impairs tyrosine phosphatase activity [24], This 
also triggers a loss of endothelial cell-to-cell junctions resulting in an increase in EC 
permeability at these sites.
In the final steps of the process, the monocytes migrate through these 
endothelial junctions into the subendothelial space. In order for this movement to 
occur the monocytes have to form new adhesion sites and break old ones. Recently, 
junctional adhesion molecules (JAMs) present on both ECs and monocytes have
5
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been shown to function as regulators of this transendothelial migration [25, 26]. 
platelet-endothelial cell adhesion molecule-1 (PECAM-1) is another junctional 
molecule present on both monocytes and ECs that may assist in this movement 
[27],
The transendothelial migration of monocytes is also driven by a chemotactic 
cytokine concentration gradient. Chemotactic cytokines, better known as 
chemokines, are a large family of small (8 to 14 kDa) extracellular ligands that 
interact with 7-transmembrane-spanning G-protein-coupled receptors [28] and are 
released by ECs, smooth muscle cells (SMCs) and monocytes already present in the 
artery. Monocyte chemoattractant protein-1 (MCP-1) is the chemokine most 
closely associated with atherogenesis. MCP-1 interacts via the C-C chemokine 
receptor-2 (CCR2) [29] on the surface of the monocytes.
The third major characteristic of early lesion development is foam cell 
formation. Once monocytes enter the subendothelial space they differentiate into 
macrophages. The principle function of macrophages is to engulf particles, 
internalize them and destroy them by phagocytosis or endocytosis. Macrophages 
internalize excess lipids present in the intima by phagocytosis. As they fill up with 
lipid droplets they take on a foamy appearance in histological sections. These lipid 
filled macrophages are referred to as foam cells [30].
Intermediate Stage - Fibro-muscular Lesions
Foam cells produce growth factors that stimulate SMCs in the media to 
proliferate and migrate into the subendothelial intima. The smooth muscle cells, in 
addition to engulfing lipid, also produce more proteoglycans and extracellular
6
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matrix components. SMC proliferation and extracellular matrix (ECM) 
accumulation are characteristic of the intermediate or fibro-muscular stage of lesion 
development. All of the cells in the arterial wall are able to secrete cytokines that 
cause the SMCs in the media to migrate through openings in the internal elastic 
lamina and into the intima. These SMCs, along with the matrix molecules they 
secrete, form a cap overlying the accumulation of foam cells. It is at this point that 
atherosclerotic lesions are said to be in the intermediate or fibro-muscular stage.
Advanced Stage - Complicated Lesions
Eventually, lesions may progress to the advanced or complicated stage.
These lesions are characterized by calcification, visible cholesterol crystals and a 
core of dead foam cells and gruel composed largely of cholesteryl esters. Stress 
occurs at the shoulder regions on either side of this necrotic core. It is at these 
weakened shoulder regions that rupture may occur releasing the highly 
thrombogenic gruel and tissue factor from the core. This leads to the formation of 
clots or thrombosis that may block the flow of blood within the artery causing the 
death of tissues downstream. When this occurs in a coronary artery the death of 
heart muscle results in a heart attack. When this occurs in the brain the death of 
brain tissue results in a stroke.
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CHAPTER II
ATHEROSCLEROTIC RISK FACTORS
Risk factors related to the development of atherosclerosis were originally 
identified through epidemiological studies. The four main risk factors identified to 
date are high blood pressure, high total cholesterol, diabetes and smoking [31]. 
Other risk factors include increased age, physical inactivity, stress, a genetic 
component, and other factors such as a lack of fiber or fruit and vegetables in the 
diet. It has been estimated that the traditional risk factors such as elevated plasma 
cholesterol and diabetes explain about 50% of the genetic component. However, all 
of these risk factors combined may account for only two-thirds of the incidence of 
atherosclerosis. The possible cause of atherosclerosis unrelated to these risk factors 
is the subject of ongoing investigations and many theories have been postulated. 
The focus of the research in this thesis is on two risk factors, high cholesterol, or 
more precisely LDL cholesterol that has been oxidatively modified, and diabetes 
mellitus.
High Cholesterol
The first risk factor for atherosclerosis that was identified was high total 
cholesterol. More than 100 genes have been identified related to the synthesis, 
regulation, and transport of cholesterol in humans. This is due to the important role 
that cholesterol plays in many life sustaining processes such as cellular membrane
8
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physiology, dietary nutrient absorption, reproductive biology via steroid hormones, 
stress responses, salt and water balance and calcium metabolism [32]. It therefore is 
a striking paradox that this important life sustaining substance has been found to be 
responsible for the leading cause of death in the industrialized world.
Elevated total serum cholesterol is unique among all the other risk factors in 
its ability to promote the development of lesions in the absence of any of the other 
risk factors. Humans with low plasma cholesterol levels have lower levels of 
atherosclerotic disease even when other risk factors, such as smoking and 
hypertension, are present. It has been demonstrated that a 1% decrease in plasma 
total cholesterol concentrations is associated with a 2% decrease in the incidence 
of coronary artery disease over a period of 5-8 years [33], Five major statin trials 
have provided conclusive evidence of the benefits of reducing cholesterol 
concentrations [34-38]. Risk factors, other than increased plasma cholesterol, can 
accelerate the atherosclerotic process, but in the absence of dyslipidemia they 
contribute little to atherogenesis [39]. In addition, there is no known natural 
mammalian animal model exhibiting human-like atherosclerosis in which 
atherosclerosis can be induced without altering cholesterol profiles [40]. All of 
these facts support the role of cholesterol as a causative factor in the development 
of atherosclerosis and therefore, reducing cholesterol with cholesterol lowering 
drugs, such as the statins, remains the principle means of reducing atherosclerotic 
disease.
The lipoproteins that transport cholesterol also play an important role in 
atherosclerosis. Lipoproteins are involved in the task of transporting dietary and
9
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endogenously produced lipids to where they are needed in the body. Elevated LDL, 
the major carrier of cholesterol, is a well established risk factor for atherogenesis 
[41-43] and of all the lipoproteins its role in the development of atherosclerosis has 
received the most attention.
Lipoproteins are spherical particles with lipophilic cores containing varying 
amounts of cholesteryl esters and triglycerides. The core is surrounded by a 
monolayer of phospholipids. Also around the core is one or more long chain 
polypeptide(s) called an apoprotein (apo) that enables the transport of core 
lipids within the aqueous environment of the blood and tissue. Chylomicrons 
transport exogenous dietary lipids. Very low-density lipoprotein (VLDL), LDL, 
and high-density lipoprotein (HDL) transport endogenous lipids made mainly by 
the liver.
VLDL synthesized by the liver contains high levels of triglyceride fatty 
acids. On the surface of VLDL there are two apoproteins, apoB-100 and apoE 
enabling the transport of these triglyceride fatty acids either to muscles to be used 
for energy or to adipose tissue to be stored for future use. After releasing these 
triglyceride fatty acids, the remaining VLDL particle is metabolized to a smaller 
cholesterol-rich lipoprotein, LDL, by further removal of triglycerides and a 
dissociation of apoE.
LDL is the major carrier of cholesterol to the cells of the body. The core of 
LDL is high in cholesterol but also contains fatty acids and some lipid soluble 
antioxidants such as a-tocopherol (vitamin E). ApoB-100, the remaining apoprotein
10
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from VLDL, is the only apoprotein on LDL. LDLs principle atherogenic 
mechanism is its major role in supplying cholesterol to tissues.
In contrast to VLDL and LDL, HDL is athero-protective [44, 45]. The core 
of HDL contains less cholesterol than LDL and much less triglyceride than VLDL. 
ApoA-1 is the predominant apoprotein on HDL. HDL’s principle athero-protective 
mechanism is its major role in reverse cholesterol transport (RCT), the 
transportation of cholesterol from the peripheral tissues back to the liver. In mice 
injected with cholesterol, the rate of cholesterol clearance was highly correlated 
with the level of HDL providing evidence that RCT contributes greatly towards 
decreasing the risk of atherosclerotic lesion formation [46].
Excess cellular cholesterol has harmful effects on the cell membrane. 
Some of these effects include a loss of fluidity leading to the dysfunction of integral 
membrane proteins and receptors and a disruption of membrane domains causing a 
disruption of normal signaling events [32]. The accumulation of cholesterol in 
arterial cells can occur via three mechanisms -  the endogenous synthesis of 
cholesterol by the cells themselves, the uptake of cholesterol-rich lipoproteins such 
as LDL via receptors on the cell surface, or by receptor independent insudation. 
Multiple pathways have evolved to protect cells against excess cholesterol and the 
harmful effects of its accumulation [47].
Cholesterol levels in the cells regulate the production of endogenous 
cholesterol by the cell via a feedback mechanism. When the cholesterol levels in 
the cytoplasm are low, sterol regulatory element-binding pProtein -  1 (SREBP-1), a 
125 kDa transcription factor that is attached to the nuclear envelop and endoplasmic
11
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reticulum, [48, 49] is cleaved and activated. SREBP-1 can then enter the nucleus, 
where it binds and activates the transcription of genes that are involved in the 
making of endogenous cholesterol. Three-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase, the rate limiting enzyme required for the synthesis of 
endogenous cholesterol, is one of the genes upregulated. The increased production 
of HMG-CoA results in an increased production of endogenous cholesterol by the 
cell. An elevated level of cholesterol in the cell inhibits HMG-CoA reductase 
leading to a decreased production of endogenous cholesterol. The down regulation 
of endogenous cholesterol synthesis is one way in which the body attempts to 
prevent excess cellular cholesterol accumulation.
Cholesterol levels in the cytoplasm are also capable of regulating the 
expression of the low density lipoprotein receptor (LDL-R), a cell surface 
transmembrane protein, again through the action of SREBP-1 which activates the 
transcription of the LDL-R gene. The role of LDL-R in the regulation of the 
plasma cholesterol level has been well established [50, 51]. Upregulation of the 
LDL-R leads to the enhanced uptake of LDL from the plasma thereby lowering the 
circulating cholesterol levels and increasing cholesterol within the cell [52]. LDL is 
recognized by the cells via the attachment of the N-terminal domain of the apoB- 
100 molecule on the LDL surface to the LDL-R. Upon attachment to the receptor 
both the LDL and the receptor undergo endocytosis. Once inside the endosomes, 
the low pH causes the LDL particle and its receptor to dissociate. The receptor may 
then be recycled to the cell membrane where it may bind to additional LDL. 
Meanwhile the LDL particle is degraded in the lysosomes. The protein components
12
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undergo hydrolysis to their individual amino acids and the lipid components 
undergo hydrolysis to free cholesterol. The hydrolyzed products may then exit the 
lysosome and enter the cytoplasm of the cell.
This receptor-mediated uptake of LDL observes saturation kinetics. When 
cholesterol levels reach the appropriate level in the cell the cleavage of SREBP-1 is 
inhibited. It can no longer enter the nucleus and activate the transcription of the 
LDL-R. As a consequence, LDL-Rs on the cells surface are down-regulated 
decreasing the removal of LDL from the plasma by this method and increasing 
plasma LDL levels. This receptor mediated process accounts for approximately 
88% of the degradation of plasma LDL in mice, 73% in hamsters, and 72% in 
rabbits. The amount of plasma LDL degraded by the LDL receptor system can 
range from 33 - 66% in humans and averages around 58% in humans consuming 
diets relatively low in cholesterol content [53]. The increasing plasma LDL levels 
seen in humans as they age is generally due to a decrease in the number or 
upregulation of LDL-Rs resulting in a decreased capacity to remove LDL from the 
plasma [54, 55]. While the down-regulation of the LDL-R is another way in which 
the body attempts to prevent excess cellular cholesterol accumulation it can lead to 
an increase in plasma LDL levels and the adverse consequences associated with 
such as increase.
When plasma cholesterol levels are elevated, more LDL may enter 
through the endothelial cell gap junctions in a non-receptor mediated way. Usually 
the arterial EC barrier is selectively permeable. The glycocalyx, charge, and 
compactness of the endothelial basement membrane contribute to its selectivity
13
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toward molecules based on charge and size [56]. The single contiguous layer of 
ECs lining the arteries has both tight and gap junctions and the space between the 
gap junctions is about 260 Angstroms. The average size of an LDL particle is also 
260 Angstroms but ranges anywhere from 200 to 300 Angstroms. Particles less 
than 258 Angstroms can easily pass through the gap junctions. A decrease of only 
5% in the diameter of LDL can result in a 50% increased rate of LDL uptake [57, 
58] through normal gap junctions.
Under normal plasma cholesterol levels passage through endothelial cell 
gap junctions usually accounts for approximately 42% of the LDL plasma clearance 
in humans with normal LDL-R activity. In those that lack LDL receptor activity it 
is responsible for 100% of the LDL clearance that takes place [53, 59-62], Unlike 
the receptor dependent process, which occurs primarily in the liver, 60 -  70% of the 
receptor-independent transport activity occurs in extrahepatic tissue [53, 59, 60]. 
This non-receptor mediated uptake of LDL observes linear uptake kinetics, not 
saturation kinetics, in response to the plasma LDL concentration [63]. LDL 
particles are therefore able to cross the endothelium and enter the intimal space in 
direct proportion to their serum concentration.
Elevated LDL probably plays an even bigger role in initiating and 
perpetuating atherosclerosis than was initially believed [13] because it is now 
known that it is not only the amount of LDL but also particle size and oxidative 
state that is important in the development of atherosclerosis. Smaller and/or 
oxidized LDL particles have been shown to be more atherogenic than native, 
normal sized LDL particles. Since smaller LDL particles are more atherogenic but
14
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contain less cholesterol than the larger LDL particles measurement of LDL 
cholesterol may not be the most accurate indicator of atherogenic potential. A more 
accurate measurement may be the determination of the number of LDL particles. 
Since there is only one apoB molecule on each LDL particle, the number of 
particles can be determined by determining the number of apoB molecules. 
However, there is also one apoB molecule on each VLDL particle and every VLDL 
particle ends up as an LDL particle. The assumption therefore might be that there 
would be a 1:1 ratio between these two particles but the biologic half-life of an LDL 
particle is at least nine times longer than that of a VLDL particle [64] so there is 
generally a ratio of nine LDL particles to every one VLDL particle in the blood. 
Measuring the number of plasma apoB particles, 90% of which is LDL associated, 
[65] is therefore a better method in determining LDL atherogenicity than measuring 
LDL cholesterol totals.
Endothelial dysfunction also results in an increase in permeability and 
allows more of the small, dense LDL particles to enter. There are several theories 
on how the endothelial cell barrier may become more permeable. The concept that 
is most widely accepted is that EC contraction induced by histamine, a vasoactive 
agent, causes the increased extravasation of macromolecules including lipids [56]. 
More recently it has been determined that histamine may reduce tight-j unction 
protein expression causing leaky junctions [66]. In addition, vascular endothelial 
growth factor (VEGF) makes the endothelial monolayer leaky [67-69]and focal 
leaky areas are often associated with EC division [70].
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The “response to injury” hypothesis originally proposed that endothelial 
denudation was the first step in atherosclerosis [71, 72], However, most 
atherosclerotic lesions show no evidence of endothelial denudation so this theory 
was later revised to emphasize endothelial dysfunction or “injury” rather than 
denudation [73], The response to injury hypothesis de-emphasizes the role of LDL 
in initiating atherogenesis and proposes that the initial event in atherosclerosis is an 
insult to endothelial and smooth muscles cells [73-75]. One study has demonstrated 
that endothelial dysfunction occurs following the ingestion of a high-fat meal but 
not after a low fat meal [76] and others have demonstrated that 
hypercholesterolemia causes focal activation of the endothelium in large and 
medium size arteries in humans and animals [77, 78]. Thus, it appears that 
increased plasma LDL itself may be responsible for the “injury” or dysfunction of 
ECs.
Once inside the intima, LDL particles aggregate. This aggregation of LDL 
particles tends to make it more atherogenic as demonstrated in a recent study in 
which the prevention of aggregation of LDL prohibited the formation of 
atherosclerotic lesions even in the presence of excess LDL [77, 79, 80].
Aggregation can be caused by the interaction between the LDL and the 
proteoglycans in the intima. Proteoglycans are macromolecules composed of a core 
protein and complex, long side-chain carbohydrates called glucosaminoglycans 
(GAGs). Aggregation of LDL has been shown to result primarily from direct ionic 
interactions between positively charged residues on the apoB molecule and 
negatively charges moieties of the proteoglycans. The interaction can also be
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indirect, via bridging molecules such as lipoprotein lipase (LPL) [81] secreted by 
macrophages [82, 83]. Depending on its location LPL may have an opposing 
effect. When present on the endothelium it acts on circulating triglyceride 
lipoproteins in an anti-atherogenic manner but when present in the intima it 
enhances LDL and proteoglycan binding thereby increasing the proatherogenic 
effects associated with LDL aggregation [84].
The retained LDL can further induce its own aggregation [85]. 
Aggregation can also be induced by the enzymatic lipolysis of LDL by secretory 
phospholipase A2 [86] or by secretory sphingomyelinase (sSMASE) [87, 88], In 
a study using mice expressing LDL defective in proteoglycan binding as 
compared to wild-type mice, Boren et al [80] demonstrated that the mice 
expressing the LDL defective in proteglycan binding developed less 
atherosclerosis than the wild-type mice. This supports the importance of 
proteoglycan binding as an early event in atherosclerosis.
There is some evidence that increased permeability at the sites of lesions 
does not fully explain the extent of lipid accumulation. The accumulation of 
lipids may also occur as a defect in lipid egress [89-92], Once the LDL particles 
aggregate they may no longer exit the cell but become entrapped within the 
cytoplasm. Entrapment of LDL particles due to a change in their physical 
characteristics as a cause for atherogenesis is the foundation of two somewhat 
similar hypotheses of atherogenesis. One of these is the “response to retention” 
hypothesis and the other is the “oxidized LDL” hypothesis. The response to 
retention hypothesis proposes that the initiating event in atherosclerosis is the
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retention and accumulation of LDL and other lipoproteins [93]. The basis of the 
oxidized LDL hypothesis is that the LDL retained is oxidized and that it is the 
oxidation that may be the initiating event in atherosclerosis.
Oxidized LDL
While elevated levels of LDL were initially associated with the risk for 
atherosclerosis, in vitro studies suggested that LDL itself was not atherogenic [51, 
94], In fact, incubation of LDL with normal macrophages possessing normal 
LDLRs did not support foam cell formation. The idea that the modification of 
LDL increases its atherogenic potential is just a little over 20 years old [95-97]. 
Brown and Goldstein first observed that chemical modification of LDL, in the 
form of acetylation, led to foam cell formation when incubated with macrophages. 
In 1979, Hessler and colleagues [98] demonstrated that LDL that had been 
oxidized caused injury to cells in vitro and speculated that oxidized LDL (oxLDL) 
might be important in atherogenesis. It was speculated, however, that the 
presence of anti-oxidants would prevent the oxidation of LDL in vivo.
But more recently the occurrence of LDL oxidation in vivo has been 
supported by several pieces of evidence. Oxidized apo B-100 epitopes and 
increased levels of lipid peroxidation products have been detected in the LDL 
extracted from both rabbit and human atherosclerotic lesions [99]. Immuno- 
histochemical staining of atherosclerotic lesions with specific monoclonal 
antibodies also has demonstrated the presence of oxLDL [100]. In addition, 
circulating anti-oxLDL antibodies have been found in human plasma and the 
levels of this anti-oxLDL correlate with the progression of atherosclerotic lesions
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[101]. Also there is epidemiological evidence, including case-control and 
prospective cohort studies, indicating that low antioxidant consumption is 
associated with an increased risk of CVD [102-104]. Finally, studies in different 
animal models of atherosclerosis strongly suggest that progression of lesions can 
be delayed by intervention with several different antioxidants such as probucol, 
vitamin E, diphenylphenylene-diamine (DPPD), and butylated hydroxytoluene 
(BHT) [105-120]. In order to demonstrate that lesion reduction was due to the 
antioxidant activity of probucol and not its cholesterol lowering properties Carew 
et al., [121] treated one group of rabbits with probucol and another with 
lovastatin, an HMG-CoA reductase inhibitor that lowers cholesterol without 
antioxidant protection. Both groups had lower total cholesterol but only the 
probucol group had a reduction in the extent of atherosclerosis thereby 
demonstrating that the effect was due to probucol’s antioxidant not its lipid 
lowering activity.
While LDL may undergo other modifications, including chemical, 
glycation, hydrolysis, and immune complex formation, oxidation is the most 
likely in-vivo modification of LDL in the arterial wall [94, 122-124] and the one 
most closely associated with atherosclerosis [125]. However, there is still no 
confirmation that there is an absolute requirement for LDL oxidation to initiate 
atherogenesis.
Oxidation of LDL is caused by a wide variety of ROS. ROS are largely 
produced by the arterial cells themselves as either by-products of their normal role 
or as a specific response to inflammatory stimuli. All three cell types involved in
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atherosclerotic lesion development, ECs, SMCs and macrophages, are capable of 
contributing to the oxidation of LDL.
The term free radical has been equated with ROS, or oxidants, but by 
definition a radical is a molecule possessing an unpaired electron. However, with 
the exception of the hydroxyl radical most other free radicals are not strong 
oxidants. ROS such as hydrogen peroxide, superoxide, and the hydroxyl radical 
are products of normal oxygen metabolism. They are generated as a result of 
energy production from the mitochondria via the electron transport chain and as 
part of the respiratory burst utilized by white blood cells to destroy invading 
microorganisms. LDL may be modified by any enzyme system that can generate 
free radicals which includes myeloperoxidase, lipoxygenase, phospholipase and 
sphingomyelinase. All of these enzymes are present within arterial wall cells.
The oxidation hypothesis emphasizes the significance of the oxidative 
modification of LDL and the subsequent responses [126]. Oxidation of LDL occurs 
primarily in the intimal microdomains where, as previously discussed, it may be 
bound to proteoglycans and aggregated [127], Oxidation of LDL is influenced by 
extrinsic local factors such as pH, transition metal availability, the presence of 
specific enzyme systems, and local antioxidant concentrations. For example, an 
acidic environment will promote LDL oxidation by certain enzymes and may also 
effect the interactions of LDL with arterial wall components. Internal factors such 
as the antioxidant content and fatty acid composition of LDL also affect its 
susceptibility to oxidation.
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All the particles in LDL are susceptible to oxidative modification. ROS 
react with all classes of biological molecules but the polyunsaturated fatty acids 
(PUFAs) are particularly susceptible because of their double bonds. A high 
proportion of PUFAs in the LDL particle make it more susceptible to oxidation 
whereas a high proportion of monounsaturated fatty acids (MUFAs) protects 
against oxidation [128]. The molar ratio of PUFA to antioxidant in the LDL 
particle is also important in determining its susceptibility to oxidation with a higher 
ratio increasing susceptibility [129, 130], In addition, small dense LDL particles 
are more susceptible to oxidation than large less dense particles [131, 132] due to 
their lower levels of alpha-tocopherol and ubiquinol-10, two important antioxidants.
Known as lipid peroxidation, the oxidation of PUFAs in LDL is particularly 
damaging because it proceeds as a self-perpetuating chain-reaction. In lipid 
peroxidation a free radical, such as the hydroxyl radical (OH), abstracts a hydrogen 
atom from a PUFA double bond. An unstable carbon centered lipid radical is 
produced (L-). Because of its instability it undergoes a molecular rearrangement 
resulting in a more stable conjugated diene. But even the more stable conjugated 
diene reacts very quickly with molecular oxygen forming a lipid peroxyl radical 
(LOO ). The lipid peroxyl radical further propagates the peroxidation chain 
reaction by abstracting a hydrogen atom from a nearby PUFA. The resulting lipid 
hydroperoxide (LOOH) can easily decompose to form a lipid alkoxyl radical (LO-). 
These decomposed lipid hydroperoxides can undergo beta-scission reactions 
forming reactive aldehyde compounds such as malondialdehyde (MDA) and 4- 
hydroxynonenal (4-HNE). Since oxidants themselves are very short lived most
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studies focus on the products of oxidation reactions, such as MDA and 4-HNE, 
which readily combine with functional groups on proteins, lipoproteins, and DNA 
potentially altering their behavior. Alpha tocopherol can break the chain reaction 
by forming a tocopherol radical. While this is still a radical species it is one that 
has very low reactivity. The tocopherol radical can be reduced by co-antioxidants 
such as ascorbate (vitamin C) and be exported out of the lipoprotein particle into the 
aqueous phase thus leading to chain termination as opposed to chain propagation. 
HDL also contains an enzyme called paroxonase, which has been shown to protect 
LDL from oxidation and prevent accumulation of lipid peroxidation products on 
LDL. This antioxidant effect of HDL is another method, along with its role in 
RCT, by which it is athero-protective.
Once produced, reactive aldehydes can diffuse and cause cytotoxic and 
mutagenic damage [133, 134], They also readily bind to lysine groups in the apoB- 
100 protein molecule, forming Schiff bases and altering the surface charge of LDL. 
Oxidative modification of proteins may result in cross-linking, peptide 
fragmentation, or in the conversion of one amino acid to another. These 
modifications may alter the secondary and tertiary structure of the protein and in 
doing so may subject previously unexposed regions to further oxidation.
As much as 1% of the oxygen consumed by the average human may 
oxidatively modify proteins. In an elderly person 30 -  50% of their total cellular 
protein may be oxidatively modified [135] because there is less protection against 
oxidative modification in old cells and tissues than in young ones. LDL lipid 
peroxidation does not represent the only manifestation of oxidative stress that may
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be important in atherosclerosis. Recent research indicates that other oxidative 
events may be present and could play a role in atherogenesis including the 
nonenzymatic oxidation of the phospholipids in LDL particularly those containing 
arachidonic acid at the sn-2 position [136]. Comprehensive reviews of the 
oxidative modification hypothesis of atherosclerosis have been published [137- 
139],
LDL that is oxidized is not a single, well-defined entity. Its structural and 
physical properties vary according to the degree of oxidation [140]. The degree of 
oxidation is affected by the type of oxidant and the length of exposure to the 
oxidizing environment. Native LDL itself is heterogeneous and therefore a 
homogeneous product from oxidation would be impossible, particularly since there 
are many different components of the LDL particle such as cholesterol, 
phospholipids, cholesteryl esters, triglycerides and the protein portion that all may 
be oxidized to varying degrees [141]. The degree of modification can range from 
“minimal” (mmLDL), where the LDL particle is still recognized by the native LDL 
receptors [142], to extensively oxidized LDL (oxLDL), where the LDL particle is 
no longer recognized by the LDL receptor.
The biological effects of oxLDL also vary according to its degree of 
oxidation and the component that is oxidized. Evidence suggests that most of the 
atherogenic effects of oxLDL are derived from oxidized lipid components. The 
induction of adhesion molecules at the endothelial cell surface, such as VCAM-1 
and ICAM-1 for the adhesion of monocytes, is affected by oxidized fatty acids and 
oxidized phospholipids, such as lysophosphatidylcholine (LPC). LPC is also
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chemotactic to both monocytes and T-cells by inducing MCP-1. All three stages of 
monocyte binding: tethering via selectins, activation, and attachment are effected. 
OxLDL is also chemostatic for tissue macrophages. This could contribute to the 
trapping of macrophages once they have entered the subendothelial space. Oxidized 
fatty acids also increase the proliferation of arterial SMCs and highly oxidized LDL 
can inhibit endothelial cell migration which may hinder the repair of ulcerated 
plaques in advanced lesions. OxLDL has also been shown to be cytotoxic to 
macrophages and endothelial cells. This may contribute to an amplification of the 
inflammatory process and the formation of the necrotic core found in advanced 
lesions. Oxidized LDL may also directly alter the vasomotor properties of coronary 
arteries by inhibiting the ability of endothelial cells to release endothelium-derived 
relaxing factor or nitric oxide (NO). In addition to these biological effects, oxidized 
lipids and oxidants also appear to activate matrix metalloproteinases (MMPs) which 
might play a role in advanced plaque instability and rupture. They also promote 
pro-coagulatory responses from both the endothelium and platelets and have many 
other atherogenic effects.
Diabetes mellitus
In contrast to the decrease in overall death rates for CVD, death rates for 
diabetes have been gradually increasing since 1986. Diabetes was the sixth leading 
cause of death in 2000, however, this is probably under reported as only 35 -  40% 
of diabetics have the disease listed anywhere on their death certificate and only 10 -  
15% have it listed as an underlying cause of death. Diabetics are also two to five 
times more likely to develop CVD than non-diabetics [143, 144]. In people with
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diabetes, risk factors for CVD include elevated fasting plasma glucose, elevated 
blood pressure, elevated cholesterol and triglycerides and obesity. These partly 
explain the 60- 70% of deaths caused by CVD in people with diabetes [7],
Diabetes mellitus is a syndrome initially characterized by a loss of glucose 
homeostasis. Normally glucose levels are elevated in the blood following a meal. 
In response, insulin, the hormone that allows glucose to enter the cells of the body, 
is secreted from the beta cells of the pancreas. Type I diabetics have a complete 
lack of insulin production due to the destruction of their beta cells. Type I diabetes 
exists in two forms; immune mediated or an idiopathic form. Regardless of the 
cause, the beta cells of the pancreas are destroyed and little or no insulin is 
produced. At diagnosis, 50% of type I diabetics have antibodies against insulin 
and/or antibodies against islet cells of the pancreas. It is estimated that 5 -  10% of 
Americans who are diagnosed with diabetes have type I diabetes. This type of 
diabetes generally has a rapid onset that occurs most frequently in juveniles and 
therefore type I diabetes was at one time referred to as juvenile onset diabetes. It 
also requires the administration of insulin and therefore has been referred to as 
insulin dependant diabetes. However, these two terms may no longer exclusively 
describe type I diabetes and therefore are no longer used.
The majority of diabetics, 90 -  95%, have type II diabetes mellitus. Type II 
diabetics are either insulin resistant (IR) or insulin deficient, depending on the stage 
and progression of the disease. The appearance of overt type II diabetes is typically 
preceded by a pre-diabetic period in which the patient displays insulin resistance 
and hyperinsulinemia but relative normoglycemia. In insulin resistance the cells of
25
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
the peripheral tissues, such as skeletal muscle, are not as sensitive to insulin and 
therefore require more insulin to take up glucose. In response to the cells being less 
sensitive to insulin the beta cells compensate by increasing insulin production 
leading to hyperinsulinemia. However, eventually the beta cells cannot secrete 
enough insulin to overcome insulin resistance. During this time the insulin levels 
remain elevated, often above normal levels, but not high enough to cause the 
peripheral cells to take up an adequate amount of glucose. Eventually the body 
cannot maintain these high levels of insulin production. The beta cells produce 
decreased insulin and hypoinsulinemia and hyperglycemia, the hallmarks of 
diabetes, develop.
From 1980 through 2004, the number of Americans with diagnosed diabetes 
more than double from 5.8 million to 14.7 million people. Including those with 
undiagnosed disease, diabetes mellitus currently affects approximately 18.2 million 
individuals in the United States; the majority of which is type II diabetes. Between 
1983 to 2003 the prevalence of type II diabetes increased from 5.9% to 13.8% 
[145]. It has been predicted that by the year 2050, 29 million American will be 
diagnosed with diabetes which will be 165% more than in the year 2001 [146].
Of great concern is the growing number of children and adolescents now 
being diagnosed with type II diabetes related to obesity [3]. The link between 
obesity and type II diabetes has caused some to suggest using the term “diabesity” 
to better describe the current epidemic. Developing type II diabetes rises with 
increasing body weight, and is about 5-10 times greater in those having a body mass 
index of 30 or above than in those with a body mass index below 25. Those with a
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body mass index of 30 or above are classified as obese [4, 9]. There are believed to 
be more than 250 million obese adults worldwide.
This does not bode well for the future. Currently an estimated 46 to 49 
million adults in the US may have insulin resistance and it is predicted that one in 
four of them will develop type II diabetes [147]. Diabetes is predicted to reach 
epidemic proportions not only in the United States but throughout the world. The 
World Health Organization (WHO) predicts that the number of people with diabetes 
will double within just one generation, from 150 million in 2001 to an estimated 
300 million in 2025. The developing world is expected to have the greatest increase 
in diabetics. In developed countries diabetes is predicted to rise by a total of 41% 
between 1995 and 2025 while in developing countries it is predicted to rise by 170 
within the same time period [148].
The cause of diabetes type II is not fully understood and is linked with not 
only obesity as discussed above, but also the lack of exercise, and hyperlipidemia. 
Obesity is associated with a low-grade state of inflammation, probably as a 
consequence of the secretion of pro-inflammatory cytokines by adipocytes that may 
underlie the insulin resistance [149]. Early in 2001, researchers identified a 
hormone called resistin which might explain the obesity-diabetes link at a 
biochemical level [150]. Resistin more recently has been determined to have a 
potential role in atherogenesis [151].
Two possible mechanisms responsible for insulin resistance include the 
activation of protein kinase C (PKC) [152] and elevated TNF-a [153], Both of 
these mechanisms affect the insulin receptor by deactivating it and interfering with
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glucose uptake into the cell [154]. The insulin receptor is composed of two 
subunits which extend through the cell membrane. When insulin binds to the 
subunits, it turns on the enzyme tyrosine kinase which causes a series of 
phosphorylations to occur on the tyrosine resides. The phosphorylated tyrosine 
activates second messengers causing the translocation of glucose into the cell [155]. 
PKC in the cell is activated when there are elevated free fatty acids. The activated 
PKC causes the phosphorylation of serine and threonine residues on the insulin 
receptor, not tyrosine. When this occurs glucose is not translocated from the blood 
stream and into the cell via the insulin receptor. TNF-a secretion increases due to 
weight gain and also negatively affects the insulin receptor [156]. It stimulates 
phosphatases in the cell to take off the phosphate groups on the tyrosine residues 
which again inhibits the translocation of glucose into the cells leading to 
hyperglycemia [157, 158].
The diabetic’s lipoprotein profile is characterized by changes in lipoprotein 
concentrations and composition [159]. On average, the plasma total cholesterol of 
diabetics is similar to non-diabetics. However, type II diabetes is associated with a 
dyslipidemia that includes increases in plasma LDL, small dense LDL, VLDL, 
lipoprotein(a), and a decrease in HDL [160]. This creates and even more 
atherogenic lipoprotein profile in the diabetic.
Patients with insulin resistance and type II diabetes also characteristically 
have elevated postprandial triglyceride-rich lipoproteins compared to non-diabetics. 
Fasting hypertriglyceridemia levels have been demonstrated to predict this 
abnormal postprandial response to a dietary fat load. A strong correlation exists
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between plasma insulin and the postprandial TG response to a fat meal, as well as to 
the postprandial levels of large YLDLs and chylomicron (CM) remnants. In the 
fasting state, increased plasma insulin, a marker of insulin resistance, is also related 
to increased fasting plasma levels of large VLDL and CM remnants [161-168].
Diabetes, types I and II, have been shown to significantly increase the extent 
and clinical complications of atherosclerosis [169, 170]. Initially the view was that 
many of the pathologic effects of diabetes were from the condition of 
hyperglycemia itself. However, it was noted that increased lesion development was 
already apparent upon diagnosis of diabetes indicating that these lesions were most 
likely developing during the euglycemic pre-diabetic state. Clinical trials have 
documented that a reduction in LDL cholesterol significantly reduces the risk of 
CVD in diabetics while a reduction of blood glucose levels has a relatively small 
effect on atherosclerosis [170].
Since the oxidative modification of LDL is an important initiator of 
atherosclerosis it was important to determine whether an increase in oxLDL was 
present in diabetics. Oxidative stress has been demonstrated to be elevated in 
diabetics [171] as indicated by decreased plasma levels of vitamins E and C, and 
increased serum MDA [172] and urinary F2-isoprostanes [173]. Fatty acid 
hydroperoxides, another indicator of oxidative stress, are elevated 2 to 3 fold. 
Diabetics also have elevated levels of autoantibodies to oxLDL [174] and the 
resulting immune complexes between oxLDL molecules and their autoantibodies 
are more readily taken up by macrophages causing the accumulation of cholesteryl 
esters and an increase in the release of 11-1 and TNF-a. In addition, the LDL of
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diabetics has a higher affinity for proteoglycans ex vivo [175, 176] and appears to 
be more prone to oxidative modification than that of non-diabetics [177]. The 
source of free radicals in diabetes is not completely understood but cells may 
produce increased superoxide when exposed to glucose and there may be diabetes 
associated mitochondrial dysfunction increasing mitochondrial generation of ROS. 
Elevated glucose has also been shown to increase the expression and activity of 12- 
lipoxygenase in SMCs [178]. Therefore, while the greater risk for and development 
of atherosclerosis in diabetics could be due to a number of factors including 
dyslipidemia, hyperglycemia, and insulin resistance, increased oxidative stress 
appears to play an important role.
One of the effects of increased oxidative stress may be to exacerbate another 
process known as glycation. Chronic exposure of proteins to increased glucose 
concentrations in diabetics leads to the formation of advanced glycation end- 
products (AGEs) [179]. Oxidation and nonenzymatic glycation are mutually 
reinforcing processes leading to glycoxidation. All three processes, glycation, 
glycoxidation, and oxidation are complex interrelated processes. For example, 
glycated LDLs are more oxidizable than nonglycated LDLs and increased lipid 
oxidation appears to be sufficient to cause AGE formation in euglycemic animals 
[180]. Carboxymethyl lysine (CML), an irreversible advanced stage molecular 
structure generated through glycoxidation, [181] is increased in the atherosclerotic 
lesions of diabetics. One study demonstrated that the development of 
atherosclerosis is synergistically promoted by glycoxidation and lipid peroxidation
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of LDL [182]. This accelerated atherosclerosis is a major cause of morbidity and 
mortality in diabetics.
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CHAPTER III
SCAVENGER RECEPTORS
Since it was determined that oxLDL was the ultimate source of cholesterol 
that accumulated in developing foam cells, investigators initially thought that 
foam cell formation was mediated by the LDL-R. However, patients without 
functional LDL-Rs had early atherosclerosis with foam cells similar to those that 
developed in people with functional LDL-Rs, demonstrating that functional LDL- 
Rs were not required for foam cell formation. In addition, macrophages 
completely lacking LDL-Rs could become foam cells. The uptake of oxLDL by 
macrophages was eventually demonstrated to take place by way of a “scavenger 
receptor” [183]. Unlike the LDL-R, scavenger receptors (SRs) do not down 
regulate in the presence of high LDL concentrations. Macrophages may 
therefore continue to take up oxidized LDL until they become engorged with 
stored cholesterol.
The expression of SRs is modulated by various growth factors, 
inflammatory cytokines, chemokines, lipids, cholesterol and modified 
lipoproteins, all of which are present within the atherosclerotic lesion [184], SRs 
were originally implicated in the pathological deposition of cholesterol in the 
foam cells of atherosclerotic lesions through receptor-mediated uptake of 
modified LDL. However, other functions of SRs, including endocytosis, 
phagocytosis, adhesion, and signal transduction triggered by the binding and
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uptake of modified LDL, have subsequently been determined to also be involved 
in the development of atherosclerosis.
There are six different classes of SRs. All are similar to the LDL-R in that 
they are cell surface transmembrane receptors. The name scavenger receptor was 
well chosen, because SRs recognize a spectrum of structurally unrelated ligands 
and although each scavenger receptor shows a broad specificity that often 
overlaps that of another scavenger receptor, a clear preference for certain ligands 
by each receptor is apparent [184]. While the ligands are themselves unrelated 
they all share one similarity in that they are all negatively charged 
macromolecules. OxLDL is one such negatively charged macromolecule. Other 
modified lipoproteins recognized by scavenger receptors, include acetylated LDL, 
glycoaldehyde, which is an AGE-modified LDL, and nitrate-modified LDL. SRs 
also bind other ligands such as thrombospondin, collagen, phosphatidylserine, 
liposomes, bacterial components such as endotoxin, and apoptotic cells [184]. In 
vivo, oxLDL binding and uptake by macrophages appears to be the most relevant 
for the atherosclerotic process.
SRs also participate in the recognition and clearance of apoptotic cells and 
bacteria [185]. Removal of dead or apoptotic cells is important both for 
embryological development and for maintaining tissue homeostasis. The 
recognition of oxLDL by SRs may be explained by the structural similarities 
between cell membranes and lipoproteins. Both consist of phospholipids, 
cholesterol, and (glyco)protein. Oxidative damage to a lipoprotein particle may 
create epitopes that resemble the epitopes expressed by cells that undergo
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apoptosis or by senescent red blood cells [186]. Thus, macrophages are 
responding in a protective manner by clearing the tissues of dead cells.
The first scavenger receptor was discovered on macrophages and was 
called scavenger receptor A (SR-A). The molecular characterization of SR-A 
took place in 1990 when it was finally cloned [187]. In recent years, several new 
members of the scavenger receptor family, such as CD36, SRB1, and CD68 have 
been discovered on macrophages and have also been cloned on the basis of their 
ability to recognize modified lipoproteins [188, 189],
The receptor focused on in this study was the first scavenger receptor 
originally identified as an endothelial cell scavenger receptor [190, 191]. Based 
on sequence data showing that the molecule has a long C-terminal extracellular 
domain belonging to the C-type lectin family, the molecule was termed LOX-1 
for lectin-like oxLDL receptor-! [191]. LOX-1 is a type II membrane protein 
classified as a class E scavenger receptor that has been demonstrated to act as a 
cell-surface receptor of oxLDL [192, 193]. It does not share any homology with 
any other of the known SRs. In addition to the extracellular C-type lectin domain, 
LOX-1 consists of a hydrophobic transmembrane domain and a cytoplasmic N- 
terminal domain. Although the calculated mass of this protein is about 3 1 - 3 2  
kDa [192-194], it is found endogenously as a 40 kDa precursor form with N- 
linked high mannose carbohydrate chains and a 48 - 50 kDa mature form due to 
further glycosylation [193]. This is the result of post-translational modification of 
four potential N-linked glycosylation sites located on the C-terminal domain. The 
N-linked glycosylation of LOX-1 appears to be necessary for adequate
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transportation to the cell surface and efficient ligand binding [193]. The lectin 
domain is the functional domain that recognizes LOX-1 ligands and the C- 
terminal end residues and several conserved positively charged residues spanning 
the lectin domain are essential for oxLDL binding. In the N-terminal cytoplasmic 
domain there are several potential phosphorylation sites. An unknown protease is 
able to cleave the N-terminal amino-acids at two cleavage sites, located in the 
membrane proximal extracellular domain, releasing soluble LOX-1 (sLOX-1) into 
the bloodstream. The LOX-1 receptor is not only present on the endothelium of 
vascular rich organs (liver, lung, brain, placenta), the aorta, coronary and carotid 
arteries, but also on macrophages and vascular SMCs in atherosclerotic lesions, 
including those of humans [193, 195],
It has been demonstrated that LOX-1 promotes the binding, internalization 
and degradation of oxLDL, [196], lysophosphatidylcholine, and oxidized fatty 
acids. The binding of oxLDL to LOX-1 may trigger the activation of the NF-kB 
signal transduction pathway [197]. Binding experiments have demonstrated that 
native LDL and acetylated LDL do not compete with LOX-1 for uptake of 
oxLDL [191, 196]. LOX-1 expression has been shown to be upregulated by 
minimally oxidized LDL but not extensively oxidized LDL. TNF-a [198], 
transforming growth factor beta (TGF-|3) [194, 199], angiotensin II [200] and 
shear stress also upregulate LOX-1.
The binding of platelets to LOX-1 enhances the release of endothelin-1 
from ECs inducing endothelial dysfunction and promoting the atherogenic 
process [201]. LOX-1 is also a key factor in oxLDL-mediated monocyte
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adhesion to human coronary artery endothelial cells [202]. LOX-1 has the ability 
to capture leukocytes under physiologic shear stress suggesting that it functions as 
a vascular tethering ligand [203]. C-reactive protein (CRP) also enhances 
endothelial LOX-1 expression [204] and increases both human monocyte 
adhesion to endothelial cells and oxLDL uptake by these cells. Heparin-binding 
epidermal growth factor-like growth factor (HB-EGF), a potent mitogen for 
vascular SMCs, also induces LOX-1 expression in cultured bovine aortic SMCs 
[205], Homocysteine, an atherogenic amino acid believed to exert its effects 
through oxidative stress, enhances endothelial LOX-1 gene expression in aortic 
ECs. The antioxidant N-acetylcysteine (NAC) suppresses this enhanced 
endothelial LOX-1 gene expression [200]. LOX-1 is also known to bind 
apoptotic cells and oxidized red blood cells.
OxLDL stimulated LOX-1 expression in human coronary artery ECs is 
downregulated by pre-treatment with statins [195, 206]. A high concentration of 
statins (10 uM) is more potent than a low concentration (1 uM) in downregulating 
LOX-1. LOX-1 on ECs induces reduction of nitric oxide (NO) release and up- 
regulation of adhesion molecules, thereby contributing to the development of 
atherosclerosis [207]. Antisense to LOX-1 mRNA decreases LOX-1 expression 
and the subsequent expression of the adhesion molecules, VCAM-1, ICAM-1 and 
the selectins [206]. Monoclonal antibodies against LOX-1 can inhibit oxidized 
LDL binding to cultured bovine aortic ECs by 50 to 75%. This indicates that 
LOX-1 may play an important role in the uptake of oxLDL from the bloodstream 
and the development of atherosclerotic lesions.
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The presence of LOX-1 has been demonstrated in both animal models of 
atherosclerosis and human atherosclerosis. LOX-1 ligand levels have been shown 
to be significantly elevated in the plasma of Wantanabe heritable hyperlipidemic 
rabbits [208]. In addition, increased expression of LOX-1 has been demonstrated 
in the initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits 
primarily within the aortic intima at the earliest stages of lesion development and 
most prominently in the ECs of the lesions. However, even the ECs in the non­
lesion areas exhibited distinctive LOX-1 immunoreactivity in these animals [209] 
demonstrating that the hyperlipidemia itself increased the LOX-1 expression. 
LOX-1 has also been shown to be significantly increased in diabetic rat aorta with 
the most immunoreactivity in ECs, particularly those in the bifurcations of artery 
branches from the aorta [210]. Studies have also shown that the monoctye- 
derived macrophages of humans with type II diabetes also over express LOX-1.
Diabetics, as discussed previously, have dyslipidemia but not necessarily 
hyperlipidemia. Even without hyperlipidemia, diabetics have markedly 
upregulated LOX-1 expression. LOX-1 has been shown to bind not only oxLDL 
in diabetics but also AGEs, the non-enzymatically glycosylated proteins which 
accumulate in the vascular tissues of the aging and diabetic populations [211].
In cultured aortic ECs, streptozotocin-induced diabetic rat serum and 
AGE-bovine serum albumin (BSA) induced LOX-1 expression, while control rat 
serum with only high glucose did not. This suggests that glucose alone is not 
responsible for the induction of LOX-1 expression on ECs but that plasma 
proteins that have undergone glycosylation are the more likely culprits [212]. In
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contrast, in vitro studies using human monocyte-derived macrophages 
demonstrated that incubation with glucose would enhance both LOX-1 gene and 
protein expression in a dose- and time-dependent manner. Antioxidants, PKC, 
mitogen activated protein kinases (MAPKs), nuclear factor-kappaB (NF-kB), and 
activated protein-1 (AP-1) inhibitors all were able to abolish the induction of 
LOX-1 gene expression in macrophages by glucose. [213]. Whether it is glucose 
alone that increases LOX-1 expression, as seen in human monocyte-derived 
macrophages, or whether it takes AGE-modified plasma proteins to increase 
LOX-1 expression as seen in cultured aortic ECs, both processes are indicative of 
the relevance of the study of LOX-1 in relation to diabetic atherosclerosis.
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CHAPTER IV
THE SYRIAN FXB HAMSTER
Animal models of human diseases are often used in experimental studies because 
environmental and genetic backgrounds can be strictly controlled in animal models. This 
control is difficult when studying human disease in humans as environmental and genetic 
backgrounds differ from individual to individual and population to population. Recently 
much of the animal research has used gene “knockouts” where targeted genes are deleted 
from the animals. However, scientists must be cautious in their interpretation of results 
from gene knockout animals since gene deletions may have secondary phenotypic effects 
and are not tissue specific. Additionally, gene deletions may cause compensatory 
changes in the expression of other genes in these animals and this may also confound the 
results.
The Syrian hamster, Mesocricetus auratus, has been used extensively as an 
experimental animal model since 1930 when hamsters captured in Syria where bred at 
Hebrew University. The normal life span of the Syrian hamster is up to 3 years. While 
the hamster is classified as an omnivore and is capable of predation, some of the 
structural features of its gastrointestinal tract and some features of its feeding behavior 
are more similar to that of an herbivore [214], Hamsters have a rigid and regular two 
hour feeding schedule, feeding 12 times throughout the day and night in a 24 hour period. 
They will normally consume about 2.5 calories/lOOg at each 2 hour interval when fed ad 
libitum or about 30 calories/1 OOg per day for a sedentary hamster. Hamsters have
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limited physiologic ability to withstand food deprivation. Their basic response to a 
shortage of food is to reduce their energy expenditure rather than increase their food 
consumption when food again becomes available. Fasting for as short as 24 hours may 
induce starvation anorexia or may decimate the bacteria and protozoa in the forestomach 
and cecum necessary for digestion. Weight loss greater than 22% may cause 
hypothermia, unconsciousness and whole-body tremors [215, 216].
Lipoprotein Metabolism
Hamsters have long been used as an animal model for the study of lipoprotein 
metabolism [217] since their lipoprotein metabolism has many attributes in common with 
humans [218, 219]. Hamsters have relatively high serum LDL concentration when 
compared to mice and rats [220]. In the hamster, as in humans there are appreciable 
levels of LDL as well as HDL [221]. And although unlike humans, HDL is the 
prominent lipoprotein present in hamster plasma, at least one third of the cholesterol is 
associated with the LDL fraction under normal dietary conditions [222]. The apoprotein 
B concentration is sevenfold greater in hamsters than in rats. In rats, 47% of apoprotein 
B is associated with LDL, while in hamsters, 70% of apoprotein B is associated with 
LDL [223, 224], In general the apoprotein profile of the hamster has many similarities to 
that of humans. However, there is a difference in apoE expression between humans and 
hamsters. ApoE is found in the LDL fractions of hamsters but very little is found in the 
LDL fractions of humans. ApoE is also a more prominent constituent of VLDL in 
hamsters than in humans. Overall the plasma lipoprotein profile of humans in more 
analogous to hamsters than to mice or rats [225].
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Unlike livers from rat or mouse, the liver of the Syrian hamster secretes only 
apoB-100 containing VLDL, as is the case in humans [226]. Apoprotein B-48 containing 
lipoproteins are of intestinal origin only [227] in hamsters and in humans. This tissue- 
specific expression of apoB-100 by the liver only and apoB-48 by the intestine only is a 
distinct advantage of the hamster model [227, 228] over the mouse and rat model. 
Hamsters have also been shown to express plasma cholesteryl ester transfer protein 
(CETP) activity which is regulated by the level of cholesterol-containing lipoproteins in 
plasma as is the case in humans [229, 230]. Rats do not express CETP activity [231],
The hamster LDL-R receptor gene has been isolated and characterized and shows 
strong sequence and structural similarities to the human gene [232], The receptor- 
dependent transport of LDL in the hamster is also similar to humans. In the hamster, the 
liver is the major site for the removal of plasma LDL, accounting for 73% of the LDL 
degradation. This is due to both the high rate of receptor-mediated transport per gram of 
tissue and the large size of the liver. Most of the LDL degradation is mediated by the 
LDL-R following saturation kinetics.
In human lipoprotein metabolism, the concentration of circulating LDL is 
determined by the rate of LDL formation relative to the rate of receptor dependent LDL 
removal from the plasma [233]. When dietary intake of cholesterol and triacylglycerol is 
minimal and little lipid is reaching the liver in the chylomicron remnant, the rate at which 
LDL cholesterol is being produced and entering the plasma is low relative to the rate at 
which LDL can be removed from the plasma by receptor-dependent transport. This is 
also true for the hamster where the LDL production rate is only about 150 ug/h while the 
maximal achievable rate of receptor dependent removal is about 700 ug/h [234]. In the
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hamster, as in humans, the liver has a relatively low rate of cholesterol synthesis. The 
extensive work of Dietschy, Spady and co-workers has shown that the level of hepatic 
cholesterol synthesis in hamsters is equivalent to that found in humans, approximately 9 -  
10 mg cholesterol/day/kg body weight [234, 235], Rats and mice synthesize 
approximately 150 mg cholesterol/day/kg body weight, another reason why they are not 
good models of human lipoprotein metabolism [236],
The extrahepatic tissues of the hamster however, have high rates of cholesterol 
synthesis and may synthesize most of the cholesterol they need. Therefore, most of the 
apoprotein B-100 that is secreted from the liver in VLDL is returned to the liver carried 
either in VLDL remnants or in LDL. Relatively little is delivered to the peripheral organs 
[237]. Other animal models in which the rate of cholesterol synthesis in the liver is low 
compared to cholesterol synthesis in the whole animal are guinea pigs, pigs and several 
species of monkeys and baboons [236], However, these species are not as easy to handle 
or as inexpensive as the hamster. They also have other dissimilarities to human 
lipoprotein metabolism which makes them unacceptable as models for studying human 
lipoprotein metabolism.
Response to High Fat Diet Challenge
Hamsters are also similar to humans in their response to increases in dietary 
cholesterol in that both will demonstrate an increase in serum LDL cholesterol (Jansen, 
1989). When fed an appropriate diet, the hamster presents a more human-like lipoprotein 
profile than do many other rodent species [230, 238]. Hamsters fed a hyperlipidemic diet 
closely parallel the human type IV and type V hyperlipidmias in which serum triglyceride 
concentrations are increased [239],
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In the absence of dietary cholesterol the VLDL + LDL/HDL ratio in the hamster 
is below 1.0 but this ratio increases after cholesterol feeding to 2.6 in the FiB hamster 
strain [240], Rats and mice, on the other hand, will respond to increases in dietary 
cholesterol by activating bile acid synthesis. Therefore, they primarily down-regulate 
hepatic synthesis and up-regulate hepatic bile acid production so that the plasma 
lipoprotein concentration remains relatively unchanged [236]. This response is distinctly 
different from humans, again making rats and mice poor models for dietary cholesterol 
challenge studies. Again, other animal models that behave similarly to humans in 
response to a dietary cholesterol challenge include guinea pigs, pigs, and several species 
of monkeys and baboon. An increase in cholesterol intake by 5 -  10 times their synthesis 
rate provides a rigorous cholesterol challenge to any of these animal models [236]. But 
again, the hamster is the more inexpensive model to feed and the easiest to handle 
making them most desirable.
On average, humans take in approximately 3 -  5 mg cholesterol/day/kg/ body 
weight which is equivalent to 50% or less of that synthesized. A comparable dose of 
dietary cholesterol in hamsters is achieved by adding only 0.1 -  0.3% cholesterol to the 
hamster’s diet. If cholesterol is added at an amount higher than 0.3%, changes occur in 
liver biochemistry and plasma lipoprotein concentrations that do not have any relevance 
to the regulation of lipoprotein concentrations in humans [236], In addition to 
cholesterol, high fat must be added to the diet in order for hamsters to develop combined 
hyperlipidemia. Cholesterol alone will not have this effect and neither does high fat 
alone [241]. The addition of cholesterol alone to the diet causes a dose-dependent 
increase in the level of cholesterol esters in the liver, a progressive suppression of LDL
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receptor activity, and small increases in the LDL production rate. The addition of 
triacylglycerol containing saturated fatty acids to cholesterol containing diets lowers the 
concentration of hepatic cholesterol esters, further suppresses receptor activity, 
significantly increases the LDL production rate and as a consequence of these events, 
markedly raises the plasma LDL level [234, 235, 242, 243]. This is similar to the 
naturally occurring dietary situation in a large portion of the human population. The 
addition of saturated fat in the diet also reduces the uptake of cholesterol into the tissues 
through the LDL-R pathway [234, 242],
It takes about 4 -5 weeks for approximately 100 pools of LDL to be turned over in 
the hamster. This is when the hamster reaches a steady state in the distribution of 
unesterified and esterifled cholesterol in the liver, the level of hepatic LDL receptor 
activity, the size of LDL production, and the concentration of LDL in the plasma. In 
humans this probably takes longer than 3 months to achieve [244],
Model for Human Atherosclerosis
While most hamster strains respond to high cholesterol diets with increased 
plasma LDL, one strain, the Syrian FiB hamster is associated with an increased 
susceptibility to atherosclerosis due to a deficiency in LPL activity. The deficiency of 
LPL activity in the FiB hamster causes an accumulation of chylomicrons and to a lesser 
extent VLDL [245]. The absence of functional LPL is one of the underlying causes of 
type 1 hyperlipoproteinemia in humans and it is possible that cholesterol may exert direct 
effects on LPL gene expression.
In addition, the hybrid FjB hamster requires relatively low levels of dietary 
cholesterol to develop aortic atherosclerosis compared to other non-hybrid strains [246].
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A diet containing 0.2% cholesterol and 10% coconut oil can cause fatty streak formation 
in the ascending aorta within 2 months [238]. Hypercholesterolemic diet-induced 
atherosclerosis in the hamster model is confined initially to a lesion-prone area along the 
inner curvature of the aortic arch [230, 238]. Prolonged consumption of an atherogenic 
diet results in the development of lesions throughout the aorta [245], The lesions are 
similar to those found in humans [247, 248] characterized by the infiltration of 
monocytes, which become lipid-filled macrophage foam cells [246]. Within 12 months 
these early aortic lesions can develop into complex advanced plaques resembling human 
lesions, with a fibrous cap of SMCs, connective tissue matrix and a necrotic core 
containing cholesterol crystals [249]. Rats are resistant to atherosclerosis [250] and 
atherosclerotic lesions formed in any of the mouse models of atherosclerosis do not 
progress to the stage in which lesions promote the clinical manifestations observed in 
humans. Several species of rabbits develop atherosclerosis on high fat diets but the 
rabbit’s cholesterol metabolism is different from that of humans and they develop a 
‘cholesterol storage disease’ with lesions that are not the same as that of humans [251].
Model for Diabetic Accelerated Atherosclerosis
A major limiting factor in studying the mechanisms responsible for accelerated 
atherosclerosis in diabetes has been the lack of a suitable animal model. Diabetes 
appears spontaneously in some animal species, and several genetic models have been 
developed in rodents. However these animals are poor models of human diabetic 
atherosclerosis. The most successful approach to developing a diabetic atherosclerosis 
model has been to superimpose diabetes on a current atherosclerosis animal model such 
as the hyperlipidemic Syrian hamster. This has previously been accomplished by either
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removing the insulin producing B-cell via pancreatectomy or by the injection of a B-cell 
toxin such as alloxan or streptozotocin (STZ).
STZ Induced Diabetes
STZ, a natural compound isolated from the gram positive bacterium Streptomyces 
achromogene, was discovered in 1960 as a new antibacterial antibiotic. It is an alkylating 
agent consisting of a methyl-nitrosurea side group attached to carbon-2 of D-glucose 
[252]. The glucose moiety allows for preferential uptake of STZ into B cells via the 
glucose transporter (GLUT)-2 [253, 254].
STZ exists as a mixture of alpha and beta anomers [255]. Upon dissolution of 
powdered STZ in an aqueous buffer, equilibrium between the two anomers is complete 
within 2 hours at room temperature with a nearly equimolar mixture of the anomeric 
forms [256]. STZ is unstable in unbuffered aqueous solutions, but stable for several days 
in a buffered aqueous solution with a pH of 4.0.
STZ has been used to induce diabetes mellitus in many different experimental 
animal models including the rat, mouse, guinea pig, monkey, pig and Chinese and Syrian 
hamsters [257-267] due to its selective pancreatic P-cell toxicity. However, most species 
have a high acute mortality to STZ injection, whereas Syrian hamsters show a high 
percentage of survival after STZ injection [268]. Han et al [269] determined that a single 
injection of 40 mg/kg of STZ was the appropriate dose to induce hyperglycemia in the 
APA strain of the Syrian hamster without nephrotoxicity although approximately 10% of 
the injected hamsters fail to develop hyperglycemia.
There is over 20 years of evidence supporting B cell death in STZ treated rodents 
[270-272]. STZ causes DNA strand breaks which then activate poly ADP-ribose
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synthetase, an enzyme that polymerizes the ADP-ribose moiety of NAD to form poly 
ADP-ribose. This causes a lethal depletion of nicotinamide adenine dinucleotide (NAD) 
in the [3-cells [273-278], STZ has been shown to directly methylate DNA producing not 
only DNA strand breaks, but also alkali-labile sites, DNA adducts, chromosomal 
aberrations, micronuclei, sister chromatid exchanges, and cell death [279], Free radicals 
may also be involved in the DNA and chromosome damage produced by STZ [280], 
Gille et al. [281] demonstrated that STZ increases the generation of reactive oxygen 
species in murine islet cell cultures. STZ not only modulates energy metabolism by 
decreasing the amount of reducing equivalents such as NADH and NADPH but also by 
modulating oxygen metabolism in cells by reducing their antioxidant capacity and 
increasing mitochondrial ROS formation. Further aggravating the situation is the fact 
that intracellular metabolism of STZ also yields nitric oxide which precipitates additional 
DNA strand breaks [282], The ROS induced damage of proteins, lipids and DNA, as 
well as the depletion of energy, all contributes to the death of the (3-cells.
There are apparently essential characteristics that make the mature [3-cell 
particularly susceptible to toxins such as STZ, one of which is the expression of GLUT - 
2. However, the precursor population for both endocrine and exocrine tissue in the 
pancreas is not susceptible to damage by STZ [283], This is most likely due to an 
insufficient expression of GLUT-2 on the immature cells.
As stated previously, Syrian hamsters of the APA strain are known to enter a 
marked and continuous diabetic state after a single injection of STZ without severe toxic 
effects. STZ-induced hamsters may be able to maintain this diabetic state due to the 
proliferation of immature precursor cells that are not affected by the STZ. This was
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demonstrated by Wang et al. [284] in newborn rats injected with 100 ug/g of STZ. They 
found that while the STZ dramatically reduced the number of P-cells in islets it had little 
effect on the number of P-cells found in aggregates of less than six endocrine cells. 
Presumably, these small aggregates are neogenic and are derived from differentiation of a 
precursor cell population. The lack of an effect on these aggregates suggests that they 
may be a less differentiated, immature P-cell population not effected by STZ. Another 
possibility is that hyperglycemia may also play a role in stimulating P-cell replication 
after STZ administration. Glucose is a well-known stimulus for proliferation of pre­
existing P-cells [285]. Movassat et. al. [286] demonstrated that hyperglycemia may also 
play a role in stimulating P-cell replication after STZ administration in newborn rats with 
partial pancreatectomy. However, whether the hyperglycemia was influencing 
preexisting mature P-cells or new p-cells arising from precursor cells was not determined. 
More recently, Finegood et. al. [283] demonstrated that prior STZ treatment did not 
inhibit pancreas regeneration after 90% pancreatectomy in rats. He concluded that there 
was no evidence that hyperglycemia enhanced the formation of new endocrine cells from 
ductal precursor cells but that the possibility that moderate hyperglycemia had a trophic 
influence on preexisting p-cells in the form of hypertrophy or replication could not be 
excluded. However he did find that severe hyperglycemia, or something associated with 
it, appeared to inhibit the development of the endocrine cell mass. Rosenberg [287] 
postulated that islet-cell regeneration in the diabetic hamster pancreas could be induced 
by a local growth factor(s). Whatever the reason, Takatori et al. [288], in a functional and 
histochemical analysis on pancreatic islets of APA hamsters with STZ-induced 
hyperglycemia and hyperlipidemia, found that these hamsters could remain in a diabetic
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state because resident P-cells in the islets proliferated even after STZ injection and that 
most degenerated cells continued to maintain low levels of insulin secretion.
One problem with the use of STZ to induce the diabetic state is that the 
efficacy of STZ is highly variable between species, strain, age and laboratory. Even in 
the same species of animal receiving the same dose of STZ the results are widely variable 
[289], This limits the predictability of the effects of STZ in inducing diabetes. Therefore 
other methods of inducing diabetes and insulin resistance are currently being 
investigated.
High Fat Diet Induced Insulin Resistance
Recently it has been determined that the high fat-fed Syrian Golden hamster 
without STZ injection, in addition to being a good model of human hyperlipidemia and 
exhibiting a significant weight gain, also exhibits hyperinsulinemia and 
hypertriglyceridemia which are characteristic of the profile often observed in obese 
insulin-resistant and/or type 2 diabetic patients [241]. The high fat diet load not only 
causes impairment of insulin secretion but also leads to insulin resistance making the 
high fat-fed hamster a model of nutritionally-induced insulin resistance [290]. The 
insulin resistance is accompanied by a marked increase in intestinal apoB48 particle 
production which is an integral feature of the insulin resistant state. Peripheral glucose 
disposal stimulated by insulin is inhibited by the elevated levels of plasma free fatty acids 
in man [291, 292], The high-fat fed Syrian Golden hamster also has a significant 
reduction in whole body glucose disposal and a reduction in insulin suppression of 
hepatic glucose production [290].
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High Fructose Diet Induced Insulin Resistance
Another model of nutritionally-induced insulin resistance is the high fructose-fed 
hamster. High fructose feeding alone for a 3-week period induces significant 
hypertriglyceridemia characterized by the overproduction of intestinal apoB48-containing 
lipoproteins in both the fasting and postprandial states [293]. Hyperinsulinemia and the 
development of whole body insulin resistance in the high fructose-fed Syrian golden 
hamster, similar to the high-fat fed model, is again due to the overproduction of apoB48 
particles. However, in contrast to the high-fat fed model, the fructose fed hamster 
induces insulin resistance in the absence of significant weight gain [294]. The high fat 
high fructose fed hamster is therefore a good animal model for the study of the treatment 
of diabetic dyslipidemia [226]. This model also demonstrated insulin resistance as 
judged by elevated insulin levels during an oral glucose tolerance test (OGTT) indicating 
that it may be a useful model for the study of the interaction of diabetes and 
atherosclerosis. There may be less variability in response to high-fructose than there is to 
STZ. Additionally the use of fructose eliminates the hamster deaths related to the 
toxicity of STZ.
In conclusion, the hamster is a useful small animal model that simulates the 
interaction of diabetes and atherosclerosis because hyperglycemia and atherosclerosis can 
be easily induced and because the lipoprotein metabolism of hamsters has many attributes 
in common with humans. Additionally, hamsters develop atherosclerotic lesions and 
other diabetic complications similar to humans [295]. In the following study, combined 
diabetes and atherosclerosis was studied in STZ injected, high-fat fed Syrian FiB 
hamsters.
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CHAPTER V
MATERIALS AND METHODS
Animals, Diets, and Experimental Design
Sixty male golden FiB Syrian hamsters (Mesocricetus auratus), 9 weeks old, 
weighing between 87 grams (g) and 106 g, were obtained from Biobreeders (Watertown, 
MA). Hamsters were housed individually in rodent cages under environmentally 
controlled conditions of 20 ± 1° C at 30% to 60% humidity on a 12-hour/12-hour 
light/dark cycle with ad  libitum access to food and water. After one week of acclimation, 
animals were randomly divided into four experimental groups (Figure 1):
N -  non-lipidemic/non-glycemic hamsters fed Purina 5001 standard rodent chow 
pellets containing 0.03% cholesterol and 4.5% fat (n=14);
L - lipidemic hamsters with lipidemia induced with 0.062 kgs purified cholesterol 
(0.25%) dissolved in 3 liters of hot coconut oil (10%) wt/wt (Research Diets, Inc., 
New Brunswick, NJ) and added to 22.7 kgs Purina 5001 rodent meal with the 
same formula as the standard rodent chow pellets (n =14).
G - glycemic hamsters fed standard chow with glycemia induced by one 
intraperitoneal injection of 40 mg/kg body weight streptozotocin (Stz) (Sigma 
Chemical, St. Louis, MO) freshly dissolved in 0.1M citrate buffer pH 4.5 (n =16); 
and
L+G - lipidemic/glycemic hamsters with lipidemia induced with the same diet as 
group L and glycemia induced with the same Stz injection as group G (n =16).
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To prepare the high-fat diet, additional water was added to the final meal mix to 
achieve a moist consistency. This was compacted to a 2” depth in large Tupperware 
containers and frozen until just prior to feeding when it was defrosted and cut into 
squares.
All hamsters were weighed prior to the start of the study (time 0) and at 1, 2, 3, 
6, and 8 weeks after the start of the study. All experimental procedures were performed 
in accordance with protocols approved by the Institutional Animal Care and Use 
Committee at the University of New Hampshire (IACUC approval #010702). Hamsters 
administered STZ had 5% glucose added to their water for two days in order to 
counteract the release of insulin from the dying beta cells and prevent diabetic shock. 
After Stz injection one hamster in the G group and four hamsters in the L+G group died.
After ten weeks, seven hamsters from each group were weighed, fasted overnight, 
and anesthetized with an intraperitoneal injection in the lower right abdominal quadrant 
of Ketamine-HCL:xylazine (20mg:8mg per 100 grams body weight) in a 1 cc tuberculin 
syringe (Becton Dickinson & Co., Rutherford, NJ). The hamsters were then euthanized 
by exsanguination. A small incision was made in the abdominal wall, through the 
peritoneum. The heart was exposed by making a longitudinal cut up to the sternum and 
through the ribs left of the sternum. Blood was withdrawn from the left ventricle with a 
22 gauge 1 inch needle on a 3 cc syringe and was immediately aliquoted into one 200 ul 
Microvette 200 Z-gel tube for serum collection and two 1.3 mL Microtubes (Sarstedt, 
Newton, NC) containing 1.6 mg potassium-EDTA/ml of blood for plasma collection. 
Plasma samples were gently inverted several times and immediately spun at 1,500 x g for 
15 minutes in an Eppendorf 5415 C microfuge (Brinkman Instruments, Inc., Westbury,
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NY). Serum samples were allowed to clot for 20 to 30 minutes and then spun as above. 
After centrifugation, serum or plasma was removed and aliquots for lipids, glucose, and 
insulin analysis were placed on ice. All aliquots were frozen at - 80° C (Revco Scientific 
Inc., Asheville, NC) within 4 hours until analyzed.
To eliminate remaining blood cells and plasma proteins the vasculature of each 
hamster was immediately perfused with phosphate buffered saline (PBS) pH 7.4 by the 
insertion of a 21 gauge 1 inch butterfly needle into the left ventricle and a cut in the right 
atrium to allow an outlet for the solution. The saline was perfused for 5 minutes at the 
physiologic pressure of 100 to 120 mm Hg. Following the saline perfusion, four 
hamsters from each group were put in a plastic bag on ice. The remaining three hamsters 
from each group were perfused with 10% neutral buffered formalin (NBF) for 10 minutes 
under the same conditions as used for the saline. After 10 minutes of fixation in situ, the 
hamsters were put in a plastic bag on ice. The four hamsters from each group that were 
perfused with PBS only were dissected to remove the heart and aorta and a section of 
liver and kidney which were then placed in a vial and flushed with nitrogen gas before 
being snap frozen in liquid nitrogen and stored at minus 80° C. The three hamsters that 
were additionally perfused with NBF were also dissected to remove the heart, and aorta, 
and sections of liver, kidney and pancreas. The heart and aorta were pinned out at in situ 
length and all tissue was immersed in NBF overnight. After overnight fixation the aortic 
arch was cut into three sections of approximately 3 mm in length, proximal, medial and 
distal to the heart. Each tissue section was placed between two foam pads in a plastic 
embedding cassette and dehydrated and infiltrated overnight in the Citadel 2000 
(Shandon) carousel style automatic tissue processor. Heat and vacuum were not utilized
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in the tissue processing. The clearing agent used was Histoclear II (National Diagnostics, 
Atlanta, GA) and the paraffin used for impregnations was Paraplast Plus (Fisher 
Scientific). The embedded tissue cassettes were kept refrigerated for future sectioning. 
This procedure was repeated at week 20 on the remaining seven hamsters from groups N 
and L, five hamsters from group L+G, and eight hamsters from group G. In addition, 
plasma samples were taken from five hamsters in the N, G and L groups and four 
hamsters in the L+G group at 20 weeks for lipid hydroperoxide analysis. Lipid 
hydroperoxides were extracted that same day and the extracted samples frozen at - 80° C.
At two weeks and ten weeks after STZ injection blood glucose levels were 
evaluated using the FastTake glucometer. Hamsters with fasting blood glucose levels 
greater than 200 mg/dL at two weeks after injection (WAI) and greater than 290 mg/dL at 
10 WAI were considered hyperglycemic. Two hundred and ninety mg/dL of glucose 
represented a 62% increase in fasting glucose values over the non-treated hamsters 
average glucose values at week 10. In humans, only a 26% increase in fasting glucose 
values on more than one occasion is indicative of diabetes, therefore, the criteria used for 
the hamsters in this study was fairly strict. Since the hamsters glucose values varied by 
±30 mg/dL, this strict criteria assured that the glucose values between the non-treated 
hamsters and the glycemic hamsters were significantly different at the p<0.001 level. 
Four STZ injected hamsters did not meet the criteria and were eliminated from the study.
Lipid Analysis
Plasma aliquots for lipid analysis were thawed at room temperature (RT), diluted 
1:2 with physiological saline solution (The Butler Company, Columbus, OH), and briefly
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vortexed. Total cholesterol (TC) levels were determined by a cholesterol oxidase 
enzymatic method (INFINITY ™ Cholesterol Reagent procedure No. 402, Sigma 
Diagnostics, St. Louis, MO). Samples with TC beyond the assay range of linearity (750 
mg/dL) were further diluted with physiological saline to a final dilution of 1:8 and re­
assayed. Results were then multiplied by the dilution factors. High density lipoprotein 
cholesterol (HDL-C) levels were determined by precipitation of both low density 
lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) 
with phosphotungstic acid in conjunction with magnesium chloride (HDL Cholesterol 
Reagent (PTA/MgCb) procedure No. 352-4, Sigma Diagnostics, St. Louis, MO). The 
cholesterol concentration in the remaining HDL fraction was then assayed by the same 
enzymatic method used to determine TC. The combined cholesterol in the VLDL and 
LDL fractions (non-HDL-C) was calculated as the difference between TC and HDL. 
LDL-C could not be calculated by the Friedwald method as triglycerides in the L and 
L+G groups often exceeded 400 mg/dL. This increased level of triglycerides interferes 
with the accuracy of the Friedwald calculation. Triglyceride levels were determined by 
an enzymatic method (INFINITY ™ Triglycerides Reagent procedure No. 344, Sigma 
Diagnostics, St. Louis, MO). Samples with triglycerides beyond the assay range of 
linearity (800 mg/dL) were further diluted with physiological saline to a final dilution of 
1:10 and re-assayed. Results were multiplied by the dilution factors and quantified 
spectrophotometrically (Spectronic Genesys 5, Milton Roy Company, Rochester, NY).
Glucose Analysis
Serum aliquots for glucose analysis were thawed at RT and briefly vortexed. 
Glucose levels were determined by a hexokinase enzymatic method (Glucose (Trinder)
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Reagent procedure No. 315, Sigma Diagnostics, St. Louis, MO). Since turbid samples 
may give falsely high values a sample blank was used with all turbid samples according 
to the recommended sample blank procedure. The sample blank was prepared by adding 
the sample to physiologic saline and the absorbance of the sample blank was subtracted 
from the absorbance of the sample assayed with the glucose reagent in order to obtain the 
actual glucose concentration. Results were quantified spectrophotometrically (Spectronic 
Genesys 5, Milton Roy Company, Rochester, NY).
Lipid Hydroperoxide (LPO) Analysis
Extracted plasma samples from week 20 for LPO analysis were thawed on ice. 
Quantification of lipid peroxidation was determined using a Lipid Hydroperoxide Assay 
Kit (Cayman Chemical Co., Ann Arbor, MI) that measures the hydroperoxides directly 
by utilizing redox reactions with ferrous ions. Hydroperoxides are highly unstable and 
react readily with ferrous ions to produce ferric ions. The resulting ferric ions were 
detected using thiocyanate ion as the chromogen. Results were quantified on a 
spectrophotometric plate reader (ELX800, Bio-Tek Instruments, Inc., Winooski, VT) at 
490 nm.
Insulin Analysis
Plasma samples for insulin analysis were thawed at RT. Quantification of insulin
was determined using a rat insulin radioimmunoassay (RIA) kit (Linco Research Inc., St.
• • •  • • • 1 •Charles, MI) utilizing insulin labeled with Iodine and a rat insulin antiserum raised in
guinea pigs to determine the level of insulin by a double antibody/PEG technique. 
According to the manufacturer this antibody has been shown to have 100% specificity for
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hamster insulin. After performing the assay, remaining radioactive counts per minute 
were determined (LKB WALLAC 1282 Compugamma Universal Gamma Counter, 
Gaithersburg, MD) and a standard curve was plotted using nonlinear regression. Insulin 
levels in ng/mL were determined.
Statistical Analysis
Student’s /-test with a two-tailed measurement of P values was used to compare each 
group’s lipid, glucose, LPO, and insulin values between the 10 week timepoint and the 20 
week timepoint. One-way factorial analysis of variance (ANOVA) followed by Tukey’s 
Multiple Comparison post test was used to compare each group’s lipid, glucose, LPO, 
and insulin values within each timepoint. All analysis was done using the V2.0b 
GraphPad Prism (GraphPad Software, Inc) statistical program. Data was expressed as 
mean ± SD. Values of P < 0.05 were considered statistically significant. If the F test 
was significant, differences between subsets were performed on logarithmically 
transformed data. For correlation data, Spearman correlation coefficients were calculated 
on logarithmically transformed data.
Immunohistochemical Analysis
Immunohistochemical (IHC) analysis was performed on formalin fixed, paraffin 
embedded sections cut at 5pm and mounted on Superfrost Plus™ slides. Subsequently 
the paraffin was removed by placing slides in two 10 minute baths of toluene followed by 
rehydration of the tissue sections via 6 minute baths in 100% EtOH, 95% EtOH, ddFEO 
and final submersion in PBS.
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Slides containing sections of pancreas from hamster groups N, L, and G were first 
incubated for 5 minutes in 3% H2 O2 in water to quench endogenous peroxidase activity 
and then rinsed in PBS for 5 minutes. All incubations took place in a humidified 
chamber. Sections were then blocked with dilute goat serum contained in the 
VECTASTAIN® Elite® ABC Peroxidase Kit (Vector Laboratories, Inc., Burlingame, 
CA) and incubated at room temperature for 20 minutes. Excess serum was blotted from 
the sections. The sections were then incubated overnight at 4 0 C with a rabbit IgG 
polyclonal primary antibody to porcine insulin (ICN Pharmaceuticals, Inc., Aurora, Ohio) 
diluted with PBS containing 0.1% immunohistochemical grade bovine serum albumin to 
prevent adsorption of the antibody to the plastic microfuge tube in which the final 
dilution was made. This antibody is known to react with cytoplasmic and extracellular 
insulin in humans, pigs and rats. After rinsing in PBS for 5 minutes a biotinylated goat 
anti-rabbit IgG secondary antibody was added. This introduced biotin into the section at 
the location of the primary insulin antibody. After rinsing in PBS for 5 minutes an 
avidin:biotinylated peroxidase enzyme complex (ABC) was added. This bound to the 
biotinylated secondary antibody. Sections were again rinsed in PBS for 5 minutes and 
then Vector® VIP peroxidase substrate solution was added until the desired purple stain 
intensity developed. The section were rinsed in tap water and counterstained with 
Vector® Blue, cleared and mounted.
IHC analysis was similarly performed on slides containing sections of the aortic 
arch from hamster groups N, L, G, and L+G using an affinity-purified goat polyclonal 
antibody, ox-LDL receptor-1 (also designated LOX-1) diluted 1:10 with PBS with 1% 
bovine serum albumin. This antibody was raised against a peptide within an internal
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region of ox-LDL receptor-1 of mouse origin (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) and previously had been demonstrated to react with mouse and rat tissue. A 
Yectastain® ABC Alkaline Phosphatase enzyme kit was used containing a biotinylated 
anti-goat IgG secondary antibody make in rabbit. The substrate used was Fast Red 
(Signet Labs, Inc., Dedham, MA) and the counterstain used was Hematoxylin QS (Vector 
Laboratories, Inc., Burlingame, CA).
Following the same protocol IHC analysis was performed on hamster aortic 
sections using a rabbit anti-MDA antibody (Alpha Diagnostic International, San Antonio, 
TX) in which the MDA was coupled with keyhole limpet hemacyanin (KLH) prior to 
injection into rabbits. This antibody was also known to react with mouse and rat tissue.
Serial sections were used for all IHC protocols and run simultaneously applying 
1% bovine serum albumin in PBS in place of the primary antibody. Peptide 
neutralization was also performed using the peptide that the LOX-1 antibody was raised 
against (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The peptide was reconstituted 
in PBS to a concentration of between 0.2 -  1 mg/mL. Antibody at the same 1:10 dilution 
as used in the IHC protocol was combined with a ten-fold excess of peptide and 
incubated for 2 hours at RT. The antibody-peptide complexes were centrifuged at full 
speed in a microfuge for 15 minutes before use. During the IHC protocol the supernatant 
antibody-peptide complexes were applied to duplicate sections in place of the LOX-1 
antibody.
Photodocumentation
Representative sections from each group were examined using the 20X objective 
on an Olympus BHS-RFC microscope (Olympus America, Inc., Lake Success, NY).
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Images were captured using a Qlmaging CCD MicroPublisher digital camera and 
QCapture software (Qlmaging, BC, Canada).
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The average initial hamster weight of for all hamsters was 95.79 grams. The 
average weight increased steadily through 8 weeks of treatment to 106.5 grams. 
Hamsters sacrificed at week 10 had an average weight of 103.9 grams and hamsters 
terminated at week 20 had an average weight of 106.7 grams. There was no significant 
difference in the average weight of the 4 groups at the start of the study. There were also 
no significant differences in the initial weights within each group between hamsters at 
week 10 and hamsters at week 20.
Group Differences. At the 10 week timepoint the hyperlipidemic/normoglycemic (L) 
hamsters had significantly higher (p<0.05) body weights than the 
normolipidemic/normoglycemic (N) hamsters. While the mean weight of each group at 
the 10 week timepoint had increased over the mean initial body weight only the 
hyperlipidemic/normoglycemic (L) hamsters significantly increased their weight 
(p<0.001). There were no other significant differences between the groups at the 10 
week time point. At the 20 week timepoint there were no significant differences in body 
weights between groups.
Timepoint Differences. While the average body weight of each group at 20 weeks had 
increased over the average initial weight only the normolipidemic/normoglycemic (N) 
hamsters body weight increased significantly (p < 0.01). Between the 10 week timepoint 
and the 20 week timepoint the average weight of the normolipidemic/normoglycemic 
(N), normolipidemic/glycemic (G) and hyperlipidemic/hyperglycemic (L+G) groups was 
higher at week 20 while the average weight of the hyperlipidemic/normoglycemic (L)
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group was lower at week 20. However, there were no significant differences within each 
group at the week 10 timepoint versus the week 20 timepoint (Table 1).
Lipid Analysis
Group Differences. Comparisons between the four groups, at the 10 week timepoint and 
the 20 week timepoint produced the following results:
Total Cholesterol and non-HDL-C. The L group had significantly higher TC and non- 
HDL-C than the N or G groups at both week 10 (p < 0.001) and week 20 (p < 0.001). 
The L+G group had significantly higher TC and non-HDL-C than any other group at both 
week 10 (p < 0.001) and week 20 (p < 0.001). There was no significant difference in TC 
and non-HDL-C between the N group and the G group at either the 10 week or 20 week 
timepoint (Tables 2, 3, & 4, Graphs 1 & 2).
HDL-C. The L group had significantly higher HDL-C than the N or G group at both 
week 10 (p < 0.05) and week 20 (p< 0.001). The L+G group had significantly higher 
HDL-C than any other group at both weeks 10 (p < 0.001) and 20 (p < 0.001). At week 
10 there was no significant difference in HDL-C between the N and G groups but at week 
20 HDL-C in the G group was decreased significantly compared to the N group (p < 
0.01) (Tables 2, 3, & 4, Graph 3).
Triglycerides (TGI. The L and G groups had significantly higher triglycerides than the N 
groups at both week 10 (p < 0.001) and 20 (p < 0.05). The L+G group had significantly 
higher triglycerides than any other group at both week 10 (p < 0.001) and 20 (p < 0.001). 
There was no significant difference in the triglycerides between the L and G group at 
these timepoints (Tables 2, 3, & 4, Graph 4).
TC/HDL-C. The L group had a significantly higher TC/HDL-C ratio value than the N 
group at both weeks 10 (p < 0.001) and 20 (p < 0.01) and a significantly higher ratio 
value than the G group at weeks 10 (p < 0.001) and 20 (p < 0.05). The L+G group had a 
significantly higher TC-HDL-C ratio than the N and G groups at week 10 (p < 0.001) and
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week 20 (p < 0.001) and significantly higher than the L group at week 10 (p < 0.001) and 
week 20 (p < 0.05). There was no significant difference in the TC-HDL-C ratio between 
the N and G groups at either time (Tables 2, 3, & 4, Graph 5).
TG/HDL-C. At the 10 week timepoint the L group had almost a 3-fold increase in the 
average TG/HDL-C ratio over the N group. The G group had almost a 5-fold increase in 
the average TG/HDL-C ratio over the N group at the week 10 timepoint. Also at the 
week 10 timepoint the L+G group had a 34.5-fold increase in the average TG/HDL-C 
ratio over the N group, which was also a 7-fold increase over the G group and almost a 
12-fold increase over the L group. At the 20 week timepoint the L group had a 1.7-fold 
increase in the average TG/HDL-C ratio over the N group. The G group had a 3-fold 
increase in the average TG/HDL-C ratio over the N group at the 20 week timepoint. Also 
at the 20 week timepoint the L+G group had a 10-fold increase in the average TG/HDL-C 
ratio over the N group, a 3.5-fold increase over the G group and a 5.8-fold increase over 
the L group (Table 2, Graph 6).
Timepoint Differences. Comparisons within the four groups, between the two time 
points showed that the only significant differences within the groups when comparing the 
lipid levels of hamsters at week 10 versus those at week 20 occurred in the N group. At 
the 20 week timepoint the TC, non-HDL-C, and TC/HDL-C in the N group were 
significantly higher (p < 0.05) than at the 10 week timepoint and the triglycerides in the 
N group were significantly higher (p < 0.01) at the 20 week timepoint than at the 10 week 
tiempoint (Table 2, Graphs 1, 2, 3, 4, 5, & 6).
Glucose Analyses
Group Differences. Comparisons between the four groups at the two time points 
showed that the L+G and G groups had significantly higher glucose levels than the N 
group at both weeks 10 (p < 0.001) and 20 (p < 0.001). The L+G and G groups also had 
significantly higher glucose levels than the L group at weeks 10 (p < 0.01) and 20 (p <
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0.001 and p < 0.05 respectively). At week 10 the L group had significantly higher (p < 
0.01) glucose levels than the N group but at week 20 there was no significant difference 
in glucose between the N and L groups. There was no significant difference in the 
glucose levels between the G and L+G group at either time (Tables 2, 3, & 4, Graph 7). 
Timepoint Differences. There were no significant differences in glucose values of the N 
group between weeks 10 and 20, the G group between weeks 10 and 20, the L group 
between weeks 10 and 20, or the L+G group between weeks 10 and 20 (Table 2, Graph
7).
Insulin Analyses
At week 10 the L+G and the G groups had significantly increased insulin levels 
over the N group (p<0.001). The L group also had significantly increased insulin over 
the N group (p<0.05). The L+G group had significantly increased insulin over the L and 
the G groups (p<0.001). There was no significant difference in insulin between the G 
and L groups.
At week 20 the L+G group had significantly increased insulin levels over the N 
group (p<0.001). Although the L and G groups still had glucose values higher than the N 
group at week 20 it was no longer significant due to an increase in the insulin levels in 
the N group from week 10 to week 20. The L+G group still had significantly increased 
insulin over the L and G groups (p<0.001). The G group at this time had significantly 
elevated insulin over the L group (p<0.05) at the 20 week timepoint due to an increase in 
insulin levels in the G group and a decrease in insulin levels in the L group from the 10 
week values (Tables 2, 3, & 4, Graph 8).
Lipid Hydroperoxide (LPO) Analysis
At the 20 week timepoint mean LPO values (uM) for each group were as follows: 
5.13 in the N group, 2.81 in the G group, 5.24 in the L group and 7.80 in the L+G group. 
The L+G group had significantly higher (p < 0.01) LPO values than the G group. There
64
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
were no other significant differences between groups (Graph 1). Correlation between the 
log of total cholesterol and the log of lipid hydroperoxides in N, G, L and L +G hamsters 
at 20 weeks had an r value of 0.5033 and a p value of 0.0237 (Graphs 9 & 10).
Pancreatic Islet Histopathology
At the 10 week timepoint the islets in the pancreata of the L group are slightly 
smaller and there were fewer islets than in the pancreata of the N group. In addition the 
beta cells in the L group appeared less dense and vacuolated when compared to the beta 
cells in the pancreas of the N hamsters. The islets in the pancreata of the G group at the 
10 week timepoint were even smaller and fewer and the beta cells even more vacuolated 
than those of the L group (Figures 2 & 3).
Pancreatic Islet Immunohistochemistry
In the N group, cells immunoreactive for insulin designated by the dark purple 
stain are distributed throughout the islets. Insulin immuno-reactivity is greatly decreased 
in the islets of the age matched L group. Even though the islets in the G group were 
smaller and more vacuolated than the N and L group the immuno-reactivity appears to be 
similar to that of the L group (Figures 2 & 3).
Aortic Arch Lesion Development
At 20 weeks there was no visible atherosclerotic lesion development in the N or G 
groups. The L group had early stage, fatty streak lesions with foam cell formation. The 
most striking lesion development occurred in the L+G group where intermediate stage, 
fibro-muscular lesions included features of advanced stage, complicated lesions. These 
lesions had visible SMC proliferation characteristic of the fibro-muscular stage of lesion 
development. The core of these lesions was missing, having fallen out during sectioning.
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This indicates that the core most likely consisted of dead cells and gruel characteristic of 
more advanced lesions (Figure 4).
Immunohistochemistry for MPA and LOX-1 
MPA. There was very faint immuno-reactivity for MDA in the N group with a few focal 
areas in the SMCs and possibly some EC immuno-reactivity. There was moderately 
intense immuno-reactivity for MDA in the SMCs of the G group and visible EC immuno- 
reactivity. The foam cells in the L group were highly immuno-reactive but the SMCs had 
similar reactivity to the N group. The L+G group intense immuno-reactivity within the 
core of the lesion, and in ECs and SMCs (Figure 5).
LOX-1. The N group had immuno-reactivity for LOX-1 within the SMCs with a few 
focal areas and the appearance of some EC immuno-reactivity. There was moderately 
intense immuno-reactivty for LOX-1 in the SMCs of the G group and visible EC 
immuno-reactivity. However, not only were the foam cells in the L group moderately to 
intensely immuno-reactive but the SMCs were also highly immuno-reactive. The L+G 
group was intensely immuno-reactive within the core of the lesion and also throughout 
the SMCs (Figure 6 ).
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CHAPTER VI
DISCUSSION
Type I and Type II diabetics are prone to the same risk factors for developing 
atherosclerosis as non-diabetics, however their risk is increased by a factor of 2 to 5. In 
order to study the mechanism(s) responsible for this accelerated atherosclerosis in 
diabetics development of a suitable animal model of diabetic atherosclerosis is necessary. 
While genetic models of diabetes have been developed in rodents, and other animal 
species may develop diabetes spontaneously, they are not good models of diabetic 
atherosclerosis since they either do not develop lesions similar to humans or they have 
lipid and lipoprotein metabolism and profiles that are different from humans. One 
method that has been determined to be useful is to take an animal that is a good model for 
human atherosclerosis and superimpose diabetes. Initially pancreatectomy was utilized 
to simulate diabetes, however, without the administration of insulin these animals would 
not live long enough to develop atherosclerosis. A second method, the administration of 
diabetogenic agents that cause B-cell ablation such as STZ, has been used in animal 
models. A diabetic state has previously been induced by STZ in the APA strain of the 
Syrian hamster extensively used in Japan [296].
Objective 1
The first objective of this study was to determine whether one intraperitoneal 
injection of 40 mg/kg body weight of STZ could induce a diabetic-like hyperglycemic
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state in the Syrian F|B hamster, an atherosclerotic hamster model used in the United 
States, and whether the diabetic-like hyperglycemic state was similar to human Type I or 
Type II diabetes.
Hyperglycemia is the primary clinical manifestation of both Type I and Type II 
diabetes. The comparison of hamster fasting glucose values between the STZ injected 
hamster groups (G and L+G) and the non-STZ injected hamster groups (N and L) 
indicated that one intraperitoneal injection of 40 mg/kg body weight of STZ was 
successful in creating a hyperglycemic state in the Syrian FiB hamster. The G and L+G 
groups injected with STZ had significantly higher fasting plasma glucose levels than the 
N and L groups, at both weeks 10 and 20. After STZ injection, the fasting plasma 
glucose level of the STZ-treated groups (G and L+G) was 1.75 -  2.75 times higher than 
those of the non-treated hamsters. In similar studies with APA hamsters [288] non­
fasting serum glucose levels of STZ treated hamsters were 2 - 3  times as high as those of 
control animals. These results indicate that a single injection of STZ caused 
hyperglycemia similar to that found in human diabetes in the absence of insulin 
administration.
Of interest was that the L group also had significantly elevated glucose levels 
over the N group at week 10 but not at week 20. This lack of significant difference at 
week 20 was due to an elevation in the fasting glucose levels of the N group at 20 week 
and not to a decrease in glucose values in the L group. Elevated glucose in 
hyperlipidemic hamsters was also previously demonstrated in studies of the APA hamster 
strain [280].
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In addition to hyperglycemia, another characteristic of human diabetes is 
dyslipidemia characterized by hypertriglyceridemia, decreased plasma HDL, and 
increased small, dense LDL particles, the so-called “atherogenic lipid triad” [297-299], 
However human diabetics may not necessarily have an increase in total cholesterol or 
LDL-C concentrations. In this study there was no significant difference in total 
cholesterol between the N and G groups. This differs from what was seen previously by 
Simionescu et al. [280] in the APA strain of the Syrian hamster where higher total 
cholesterol in the STZ treated hamsters was observed. There was also no significant 
difference in non-HDL-C cholesterol between the N and G groups. This lack of 
significant increase in both total cholesterol and non-HDL-C in the F]B STZ treated 
hamsters is similar to what is seen in human diabetes.
The G group also had approximately a 4.6-fold increase in triglycerides over the 
N group at the 10 week timepoint but only a 2.1-fold increase at the 20 week timepoint. 
This was due more to an increase in triglycerides in the N group as they aged as opposed 
to a decrease in the triglycerides in the G group. Ebara et al. [300] also observed 
increases in the triglycerides of STZ treated APA hamsters by 5.6-7.8-fold over normal 
hamsters just 10 days after STZ injection. The striking elevation in plasma triglycerides 
seen in the STZ treated FiB hamster is similar to what is observed in human diabetes.
At 10 weeks there was also no significant difference between the HDL-C levels of 
the N and G groups. However by 20 weeks the G group had significantly decreased 
HDL-C from the N group. This was also previously seen in STZ treated APA hamsters 
[296]. Again, this decrease in HDL-C is similar to what has been reported in human 
diabetes.
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While there may be no increase in absolute non-HDL-C fraction which would 
contain LDL in the G group, increases noted in the TG/HDL ratio over the N group 
indicates the presence of larger amounts of small, dense LDL in the G group. At week 10 
the G group had approximately a 5-fold increase in this ratio over the N group and at 20 
weeks approximately a 3-fold increase over the N group. This increase in small, dense 
LDL is similar to what is seen in human diabetics. In this study, the STZ treated Syrian 
FiB hamster exhibited not only the hyperglycemia similar to that seen in non-treated 
human diabetics but also a similar lipid profile to that prevalent in human diabetes, 
making it a relevant model of human diabetes.
Determining whether STZ injection resulted in a model with characteristics 
similar to human Type I or Type II diabetes was more complicated. In humans, Type I 
diabetics have an absence of insulin production and Type II diabetics are characterized by 
an initial increase in insulin production in an attempt to compensate for a decreased 
peripheral sensitivity to the insulin. This initial increase in insulin is followed by a slow 
decline in insulin levels with the Type II diabetic eventually becoming hypoinsulinemic 
and hyperglycemic. It was anticipated in this study that STZ injection would destroy the 
beta cells. If all the beta cells were destroyed then no insulin would be produced. Under 
these circumstances the hamsters would not have survived without the administration of 
exogenous insulin. One of the reasons it had previously been determined that hamsters 
could survive for a relatively long time after STZ treatment without the administration of 
exogenous insulin was because of their continued secretion of insulin at a high enough 
level to allow enough glucose to enter into the cells of the body [301]. In this study the 
STZ treated hamsters not only continued to secrete insulin but had statistically significant
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increased insulin levels over the N group at both weeks 10 and 20 and over the L group 
by week 20. The plasma insulin levels indicated a hypersecretory state similar to that 
which occurs initially in human Type II diabetes.
In order to determine whether the beta cells of the STZ injected hamsters were 
still producing insulin, sections of pancreata were reacted with an anti-insulin antibody 
and visualized with chromagen. While the beta cells themselves appeared vacuolated and 
the size of the islets smaller than the non-treated hamsters the immunoreactivity for 
insulin was evident in islet remnants. The lack of dependence on insulin, and its apparent 
continued secretion from the beta cells in the STZ treated Syrian FiB hamsters appeared 
to be more reflective of type II diabetes rather than type I diabetes. It has been suggested 
by others that the L+G hamster manifests the conditions of both insulin resistance and 
insulin impairment [302] as seen in human type II diabetes.
Objective 2
The second objective of this study was to compare the development of 
atherosclerotic lesions between normal non-treated (N), hyperglycemic (G), 
hyperlipidemic (L) and combined hyperlipidemic/hyperglycemic (L+G) hamsters.
During the course of this study neither the N (Figure 1A) nor the G group (Figure 
IB) developed atherosclerotic lesions. The L group (Figure 1C) developed early fatty 
streak lesions characterized by foam cell accumulation. The most striking findings were 
the extremely more advanced fibro-muscular lesions observed in the L+G group (Figure 
ID). These fully developed intermediate stage lesions included SMC proliferation 
characteristic of the fibro-muscular stage of lesion development. In addition, the SMCs 
migrated to form a cap over a large vacant core. While this core was pulled out during
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sectioning it most likely consisted of dead cells and extracellular matrix. This core is 
characteristic of more advanced lesions.
Obiective 3
The third objective of this study was to determine whether any of the following 
factors influenced atherosclerotic lesion development in any of the four groups: glucose, 
triglycerides, total cholesterol, Non-HDL-C, HDL-C, TC/HDL-C ratio, TG/HDL-C ratio 
as an indicator of small dense LDL production, lipid hydroperoxides in the plasma, and 
MDA and LOX-1 in the vascular wall of the hamster aortic arch.
The L+G group had significantly greater lesion development than all other 
groups. The L+G group had fully developed fibro-fatty lesions by 20 weeks while the G 
group had no lesion development. In relation to the L+G group the L group had less 
advanced fatty or early streak lesions. In order to focus on what might have influenced 
this apparent accelerated atherosclerotic lesion development in the L+G group, plasma 
glucose, insulin, lipids, and lipid hydroperoxides were measured and staining for MDA 
and LOX-1 in the aortic arch was performed. It is important to note that at 20 weeks 
there were no significant differences in the weights between groups (Table 1). This 
eliminated weight as a confounding factor in any of the studies findings.
Glucose. The view that many of the pathologic effects of diabetes are from the condition 
of hyperglycemia itself is widely held. However, it should be noted that increased lesion 
development is already noted upon diagnosis of diabetes indicating that these lesions are 
most likely developing during the euglycemic pre-diabetic state.
Hyperglycemia, unique to patients with diabetes and impaired glucose tolerance, 
has been examined as a potential atherogenic factor. Hyperglycemia has been shown to
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increase glycation of proteins and nucleic acids and favor oxidative reactions in the 
microenvironment of the artery wall [303] leading to the speculation that the origin of 
diabetic vascular complications is the formation of AGEs and oxidative stress. Actually 
it is very difficult to separate these two mechanisms. Because the production of many of 
the AGEs involves oxidation and glycation the term glycoxidation is often used when 
referring to this process in diabetics. AGES are therefore glycated proteins, lipids, or 
nucleic acids that have been oxidatively modified or glycoxidized due to hyperglycemia 
and the increased oxidative stress caused by the hyperglycemia [304], Proteins may be 
further damaged by hydroxyl radicals released during glucose auto-oxidation. High 
glucose levels have also been shown to stimulate ROS through the PKC-dependent 
activation of NADPH oxidase and to stimulate mitochondrial superoxide production 
further increasing the oxidative stress in diabetics [305, 306]. Diabetes may increase 
mitochondrial generation of ROS through some diabetes associated mitochondrial 
dysfunction. In addition elevated glucose has been shown to increase the expression and 
activity of 12-lipoxygenase in SMCs.
AGEs form in LDL primarily by glycosylation of its phospholipids [307] but 
there is also the potential of glycosylation of the apoprotein B-100 molecule [308]. 
Increased glycated LDL has been demonstrated in the circulation and the vascular wall of 
diabetics and has been shown to be very sensitive to oxidation [309, 310]. It has been 
suggested that glycoxidized LDL is more rapidly taken up by macrophages than just 
oxidized LDL [311]. This modification of lipoproteins could therefore be one of the 
mechanisms for the early development of atherosclerosis in diabetics.
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RAGE, the receptor for AGE, is also increased in diabetes. The binding of AGE 
to RAGE increases oxidative stress and activation of the inflammatory response in the 
vasculature. AGE-RAGE interaction causes activation of NF-kB. This system is subject 
to a positive feedback loop in that the binding of RAGE by AGEs leads to the 
upregulation of more RAGE through this NF-AB dependent mechanism. When 
endothelial cell RAGE binds AGE, NF-&B translocation to the nucleus activates the gene 
expression of VCAM-1 [312, 313]. The increased expression of adhesion molecules in 
diabetics may further contribute to accelerated atherogenesis [314, 315].
In this study, the fasting plasma glucose values between the G group and the L+G 
group were not statistically different indicating that any differences in lesion 
development between these two groups was not due to a direct effect of glucose alone. 
Elevated glucose in hyperlipidemia has also been previously demonstrated in studies of 
the APA hamster strain [280]. It appears that glucose alone may not be a factor in the 
accelerated development of atherosclerosis in the L+G group.
Total Cholesterol, HDL-C, Non-HDL-C, and TC/HDL-C ratio. There was no 
statistical difference between the G group and the N group with regards to TC, HDL-C, 
non-HDL-C and TC/HDL-C ratio the week 10 timepoint. A higher TC/HDL ratio is 
generally indicative of a more proatherogenic lipid profile. At week 20 the only 
significant change was that the glycemic hamsters now had significantly lower levels of 
HDL-C than the non-treated hamsters. HDL-C is responsible for the removal of 
cholesterol from the tissues. Type II diabetics often have low HDL-C levels which may 
be partly responsible for the increased risk of atherosclerosis in diabetics [316], However
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the decrease in HDL-C levels was not enough to cause a significant change in the 
TC/HDL-C ratio.
In contrast to the G group, the L+G group had significantly higher total 
cholesterol, HDL-C, Non-HDL-C and TC/HDL-C ratios compared to the other three 
groups. The G group had no visible lesion development whereas the L+G group had 
more advance atherosclerosis compared to the L group. These results indicated that 
increased plasma lipoprotein levels may be responsible for the accelerated atherosclerosis 
in the L+G group and that the TC/HDL-C ratio may indeed be an accurate indicator of 
the development of atherosclerosis in the Syrian FjB hamsters.
Triglycerides. The hypertriglyceridemia seen in the G and L+G groups could be due to 
either the increased production of VLDL and chylomicrons, their decreased clearance, or 
both. A previous study determined that the hypertriglyceridemia seen in diabetic 
hamsters was not due to a difference in the amount of food consumed and that the hepatic 
output of triglycerides was actually decreased in diabetic hamsters. The study also 
determined that the increase in triglycerides was associated with a catabolic defect of 
VLDL triglyceride [300] not an increase in the production of VLDL. In addition to a 
decrease in the catabolism of VLDL triglycerides, chylomicron accumulation in the 
plasma due to impaired clearance could also be a contributing factor to the increased 
concentration of triglyceride-rich lipoproteins in the diabetic hamster.
In a previous study, diabetic hamsters demonstrated reduced lipoprotein lipase 
(LPL) activity by about one half and this deficiency in LPL activity was associated with 
an increase in susceptibility to atherosclerosis in the FiB hamster [245], LPL is a 
glycoprotein synthesized and secreted by macrophages and other cells [317]. This
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enzyme adheres to the luminal side of vascular endothelial cells and hydrolyzes 
triglycerides in chylomicrons and VLDL thereby converting these to denser lipoproteins 
such as chylomicron remnants, intermediate density lipoprotein (IDL) and LDL. LPLs 
effect on the development of atherosclerosis is uncertain. Recent studies have revealed 
that LPL on macrophages and in the plasma may have different roles with different 
effects on the development of atherosclerosis [84], Highly oxidized but not native or 
mildly oxidized LDL downregulates LPL production by macrophages [318]. Several 
studies have provided evidence that LPL secreted by macrophages promotes foam cell 
formation and accelerates atherosclerosis [319, 320].
Increased fasting triglyceride levels are characteristic of human diabetes. There is 
mounting evidence that elevated triglycerides in diabetics constitute a risk factor for 
atherosclerosis. Several studies have demonstrated that high levels of triglyceride rich 
lipoproteins and delayed remnant removal may increase monocyte adherence to 
endothelial cells inducing atherogenesis [321, 322], In patients with hypertriglyceridemia, 
serum levels of soluble E-selectin, ICAM-1 and VCAM-1 were shown to be elevated 
independently of other risk factors [323, 324], There is also some evidence that 
triglyceride-rich lipoproteins readily cross the endothelial cell barrier [134, 325],
All three treated groups of hamsters (G, L, and L+G) had significantly increased 
triglycerides over the non treated hamsters. The L and G groups had approximately a 4 - 
5-fold increase at the 10 week timepoint but only a 2 - 3-fold increase at the 20 week 
timepoint. This was due to an increase in triglycerides in the N group at 20 weeks as 
opposed to a decrease in the triglycerides in the G and L groups. Ebara et al. [300] also
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observed increases in the triglycerides of STZ treated hamsters by 5.6 -  7.8-fold over 
normal hamsters just 10 days after STZ injection.
There was an even greater increase in the triglycerides of the L+G group. Their 
triglycerides were increased 150-fold over the N group at 10 weeks but were increased 
only 66.5-fold over the N group at 20 weeks. The triglycerides in the L+G group were 
also increased 34-fold over the L and the G groups at 10 weeks and approximately 28- 
fold at 20 weeks indicating that the combination of hyperglycemia and hyperlipidemia 
had a synergistic effect on the level of triglycerides.
It has been observed that elevated plasma glucose often produces similar 
triglyceride levels to high saturated fat diets in humans but with substantially lower 
serum LDL cholesterol concentrations [326]. Indeed in this study there was no 
significant difference between the triglycerides in the L and the G groups. Since the L 
group developed foam cell lesions but the G group had no lesion development, 
triglycerides alone are probably not responsible for the lesion development in the L 
group. The difference between the G group and the L+G hamsters seems to be in the 
lipoprotein fractions. Therefore there may be a critical level of LDL-C below which 
triglyceride-rich lipoproteins do not increase the risk of atherosclerosis.
Lipolytic products of triglyceride-rich lipoproteins, such as free fatty acids 
(FFAs), have also been shown to increase the permeability of endothelial monolayers, 
enhance lipid accumulation in SMCs, promote endothelial production of inflammatory 
mediators (NF-&B, IL-8, ICAM-1), and alter the extracellular matrix synthesis in cultured 
SMCs. Studies with both endothelial cells [305] and SMCs [327] have demonstrated that
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increased fatty acids also increased oxidative stress and can increase NF-&B activation 
and the expression of NF-£B mediated genes including VCAM-1.
Fatty liver, which was evident in both the L and the L + G groups, are linked to 
insulin resistance. As a result of insulin resistance, there is an excess release of free fatty 
acids (FFAs) into the circulation leading to more FFA delivery to the liver. The liver 
converts the increased FFAs to TG which it then incorporates into an increased number 
of VLDL particles. That free fatty acids could also cause insulin resistance was first 
proposed by Randle et al., in 1963 [328]. In fact it was more recently determined that 
insulin resistance is more important than triglyceride levels in causing endothelial 
dysfunction since hypertriglyceridemia in the absence of severe insulin resistance does 
not appear to cause endothelial dysfunction [329],
Insulin resistance could also be a factor in the accelerated lesion development of 
the L+G group. At the 20 week timepoint there was no difference in insulin levels 
between the G group and the N group or between the L group and the N group. 
However, the L+G group had significantly elevated insulin over all 3 of these groups. 
Our findings suggest that the combination of hyperglycemia, insulin resistance, and the 
increased fatty acids seen in the hyperglycemic/hyperlipidemic FiB hamster may 
contribute to endothelial dysfunction and increased atherosclerosis. Moreover, this effect 
may be considered additive or synergistic.
Plasma Lipid Hydroperoxides. Increased plasma lipid peroxidation products have been 
observed in both Type I and Type II human diabetics [330, 331], Previous studies have 
demonstrated increased levels of plasma peroxides in the combined hyperlipidemic, 
hyperglycemic hamsters of the APA strain, sometimes almost double the normal
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concentration [280, 295, 332]. In this study the L+G group had significantly elevated 
lipid hydroperoxides over the three other groups. The G group did not have elevated 
lipid hydroperoxides and this could serve as another difference between the G and L+G 
groups that may be contributing to the accelerated atherosclerosis seen only in the L+G 
group.
TG/HDL ratio. The LDL levels of diabetics are often similar to non-diabetics but the 
LDL that they have are denser and have a higher affinity for proteoglycans ex vivo [175, 
176]. Epidemiologic studies have demonstrated that small, dense LDL particles are 
associated with a greater risk of atherosclerosis [333-336].
In this study there was no significant increase in the absolute non-HDL-C fraction 
containing VLDL and LDL between the N and G groups, however, differences in the 
TG/HDL ratio between these two groups indicate a potential difference in small, dense 
LDL. Small, dense LDL particles more easily infiltrate the subendothelial space where 
they aggregate and oxidize more readily than larger LDL particles. At 10 weeks the L 
group had an almost 3-fold increase in this ratio over the N group indicating that 
hyperlipidemia alone increased the level of small, dense LDL. The G group had almost a 
5-fold increase in this ratio over the N group at the 10 week timepoint indicating that 
hyperglycemia alone also increases the level of small, dense LDL. When combining 
hyperlipidemia and hyperglycemia, as in the L+G group, this ratio was increased 34.5- 
fold over the N group at 10 weeks indicating that the combination of hyperlipidemia and 
hyperglycemia had a synergistic effect in increasing small, dense LDL. At 20 weeks the 
L group had a 1.7-fold increase, the G group a 3-fold increase and the L+G group a 10- 
fold increase in the TG/HDL-C ratio over the N group. This confirms that while the G
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group had an increase in small, dense LDL particles the higher levels of cholesterol seen 
in the L+G group further increased the amount of small, dense LDL particles possibly 
contributing to the accelerated atherosclerosis seen in the L+G group.
MDA and LOX-1 in the aortic arch. In this study the presence of immunoreactivity for 
MDA and LOX-1 in the aortic arch of the hamsters were utilized as indicators of in situ 
oxidation. The oxidative modification of lipoproteins could be one of the mechanisms 
for the early development of atherosclerosis in diabetics. Diabetic patients have been 
generally described as being under enhanced oxidative stress [337] as indicated by their 
decreased plasma levels of vitamin E and C [338], and their increased serum MDA [172], 
and urinary F2-isoprostane [173]. This assertion is also supported by the presence of 
elevated levels of auto-antibodies to ox-LDL in type II diabetics [174].
The source of free radicals in diabetes is not completely understood. Endothelial 
cells may increase production of superoxide when exposed to glucose [339-341]. 
Glycated proteins are also known to lead to free radical formation causing oxidative 
stress by releasing superoxide [342] and hydrogen peroxide and activating macrophages 
through RAGE [343],
Many animal studies have shown a correlation of lipid oxidation as measured in 
blood, urine or vessel wall extracts with the development of atherosclerotic lesions [309], 
MDA is a highly reactive dialdehyde produced as a byproduct of PUFA peroxidation and 
arachindonic acid metabolism. Initially lipid peroxides are formed when PUFAs are 
attacked by free radicals. The free radicals abstract an electron from the PUFAs during 
this process. The peroxides react with neighboring PUFAs until they encounter an 
electron donor such as alpha-tocopherol or other antioxidant. This chain reaction of
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PUFAs can compromise cell membrane integrity and lead to cell death. In addition, 
when reacted with metal ions, such as iron or copper, lipid peroxides may form toxic 
aldehydes [344] such as MDA and 4-hydroxynonel (4-HNE). MDA has been found in 
atherosclerotic plaques and may be a critical factor in the endothelial cell dysfunction 
caused by FFAs [134],
In addition, aldehydes readily combine with functional groups on proteins, 
lipoproteins and DNA. MDA may modify the apolipoprotein B-100 particle on LDL 
which is normally recognized by the LDL receptor. In a previous study the LDL in 
diabetic hamsters was demonstrated to be more susceptible to oxidation than the LDL in 
non-diabetic hamsters [345]. The apoB-100 particle can also be modified via glycation in 
the presence of high glucose concentrations [346]. Therefore a person with uncontrolled 
hyperglycemia already has an increased risk for apoB modification and atherosclerosis 
[347] which may further be exacerbated by the presence of elevated aldehydes.
In this study MDA was present in the SMCs and ECs of the G group but appears 
localized to the foam cells of the L group. These two groups have similar triglyceride 
and insulin levels and small, dense LDL as indicated by the TG/HDL-C ratios. The L 
group had significantly higher TC, non-HDL-C, HDL-C, and TC/HDL-C ratio and while 
not significant higher levels of lipid hydroperoxides than the G group. While MDA in the 
aortic arch was not quantitated there was increased plasma LDL levels in the L group that 
could potentially be modified by MDA and consequently taken up by LOX-1 on ECs and 
macrophages in a non-saturation dependent manner.
The acceleration of atherosclerosis in the L+G group could be due to further 
modification of the apo-BlOO particle by glycation which may further induce LOX-1.
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The induction of LOX-1 is regulated by many factors involved in atherogenesis. One of 
the major mechanisms by which LOX-1 upregulation might induce atherogenesis is 
through its induction of endothelial dysfunction which may involve the activation of NF- 
AB at the transcriptional level [348]. The upregulation of LOX-1 in diabetics may be 
caused by their increase in fatty acids, particularly linoleic acid which is increased in 
LDL subfractions in patients with Type II diabetes. Linoleic acid has been demonstrated 
to increase LOX-1 expression in human aortic endothelial cells [349]. Remnant 
lipoproteins, which are also increased in diabetics, have been demonstrated to increase 
monocyte adhesion to human umbilical vein endothelial cells (HUVECS) through LOX-1 
receptor-coupled NF-AB-dependent nuclear transcription. NF-AB, when activated, 
upregulates proinflammatory gene expression, such as adhesion molecules including 
VC AM-1, IC AM-1, E-selectin and MCP-1 [3 50] and LOX-1 [3 51 ]. EC expression of C- 
reactive protein (CRP), an acute inflammatory marker, may also enhance endothelial 
LOX-1 expression and in doing so promote endothelial dysfunction [204]. TNF-a, a 
mediator of the acute phase response in inflammation, also upregulates LOX-1 
expression in SMCs in advanced atherosclerosis in a dose- and time-dependent manner 
[352]. It has recently been demonstrated that oxLDL may up-regulate NF-AB to a certain 
extent but higher concentrations of oxLDL may actually inhibit NF-AB activation [351].
In this study LOX-1 immunoreactivity was observed in foam cells and SMCs in 
the G group. Increased immunohistochemical staining of MDA in the SMCs was also 
evident and could therefore be responsible for the up-regulation of LOX-1 in the 
glycemic hamster. While MDA is also expressed in the L group it is localized more to 
the foam cells than the SMC. LOX-1 however is expressed not only in the foams cell but
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also in the SMCs of the L group. This indicates that LOX-1 might be induced by 
something other than oxLDL in the SMCs of the L group such as TNF-a.
83
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER VII
CONCLUSIONS
Hyperglycemia induced LOX-1 and MDA in the Syrian FiB hamster. 
Hyperlipidemia also induced the expression of LOX-1 and MDA. The combination of 
hyperglycemia and hyperlipidemia may have increased the expression of both LOX-1 
and MDA. Quantitative analysis of LOX-1 would be important to determining whether 
LOX-1 may be a potential target in the treatment and prevention of accelerated 
atherosclerosis in diabetics. The L+G group also have significantly elevated plasma lipid 
hydroperoxides over the G group and this could also have contributed to their accelerated 
atherosclerosis. However, a previous hamster study demonstrated that decreasing plasma 
lipid peroxides and cholesterol oxidation products had no effect on fatty streak lesion 
formation [345] therefore accelerated atherosclerosis in this model may not be dependent 
on the extent of LDL oxidation and oxidative stress. It is therefore important to further 
investigate the effects of LOX-1 on endothelial dysfunction in order to determine whether 
this may be a mechanism by which LOX-1 might contribute to accelerated 
atherosclerosis in diabetics.
It appears that the accelerated atherosclerosis seen in the L+G hamsters was 
mainly associated with their increased TC and non-HDL-C and not the effects of elevated 
glucose. In fact clinical trials have documented that reduction of LDL-C is associated 
with a significant reduction in risk for atherosclerosis among diabetic persons while
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reduction of blood glucose levels has a relatively small effect on macrovascular 
atherosclerosis [353].
A recent study concluded that diabetes is a strong predictor of severe but not of 
mild or moderate progression of atherosclerosis in humans [354], Our findings suggest 
that the L+G Syrian FiB hamster is a useful model for determining the mechanism(s) 
involved in the development of accelerated atherosclerosis under the conditions of 
hyperglycemia. The results of this study indicated that while hyperglycemia alone is 
probably not a cause of atherosclerosis in the Syrian FiB hamster it may contribute to the 
development of atherosclerosis when combined with elevated numbers of LDL particles 
and small dense LDL particles [355]. Kondo et al., recently proposed that there may be a 
critical size of small dense LDL-C (25.5 nm) above which triglyceride-rich lipoproteins 
do not increase the risk of atherosclerosis and that there is a critical level of TG (1,500 
mg/L) above which LDL is more susceptible to oxidation [356]. While the G group in 
this study had an increase in small, dense LDL particles, the higher levels of cholesterol 
and triglycerides seen in the L+G group further increased the amount of small, dense 
LDL particles possibly contributing to the accelerated atherosclerosis seen in the L+G 
group. In addition, the TC/HDL-C ratio appeared to be an accurate indicator of the 
development of atherosclerosis in the Syrian FiB hamsters since it was significantly 
elevated in the L+G group but not in the G group.
The elevated insulin levels in the L+G group may also have contributed to their 
accelerated atherosclerosis. Elevated insulin levels seen in the pre-diabetic phase of Type 
II diabetes may also be a contributing factor to accelerated atherosclerosis in these 
patients. Therefore treatment of type II diabetes may be best aimed at not only lowering
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LDL-C but elevating HDL, decreasing triglycerides and preventing the hyperinsulinemia 
that occurs in the pre-diabetic phase when atherogenesis occurs as opposed to treatment 
aimed at reducing the resulting hyperglycemia [357-359] in the diabetic phase only.
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Table 1 
Hamster Body Weights
Group/Weeks Initial Weight Final Weight
N/10 96.3 ± 3.5 100.8 ±4 .6
N/20 94.6 ± 5.6 109.0 ±7 .0*
L/10 94.7 ±4 .5 109.7 ±6.5**
L/20 97.8 ±4 .9 108.0 ±6 .5
G/10 96.2 ± 3.7 101.3 ±5 .7
G/20 95.2 ± 5 .0 104.0 ±7 .7
L+G/10 95.2 ±4.1 101.9 ±6 .4
L+G/20 96.5 ± 4 .4 107.1 ±7 .9
M e a n  (±  S D )  body weight (g). *Significant increase (p<0.01) over initial 
weight. **Significant increase (p<0 .001 ) over initial weight and significant 
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N vs L * * * * * * * ieieic * * * k k *
N vs G NS NS NS k k k NS k k k * * *
N vs L+G *** * * * *** k k k * * * k k k * * *
G vs L * * * * * * * NS * * * k k NS
L vs L+G * * * * * * * * * * * * * * * k k * * *
G vs L+G * * * * * * * * * * * * * * * NS * * *
*P < 0.05, ** p < 0.01, *** P < 0.001, NS = not significant. ^  indicates 
significant decrease of the second group. All others indicate significant 





























N vs L * * * 'k 'k ie * * * * * * NS NS
N vs G NS * * NS * NS * * * NS
N vs L+G * * * * * * * * * * * * * * * * * * * * *
G vs L * * * * * * * * * NS * * *
L vs L+G *** * * * * * * * * * * * * * * * *
G vs L+G * * * * * * * * * * * * * * * NS * * *
P < 0.05, ** P < 0.01, *** P < 0.001, NS = not significant. * indicates 
Significant decrease of the second group. All others indicate significant 
increase of the second group.
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Figure 1 
Experimental Design
1/  ^ hamsters 
receive STZ 60 Male Hamsters
1/2 of STZ and 
'A of non-STZ 
started on high fat diet
10 week timepoint 
samples collected from 
each group


























Normal Hamster Pancreatic Insulin Immuno-reactivity
Sections of normal hamster pancreas at 10 weeks. Purple 













































Glycemic Hamster Pancreatic Insulin Immuno-reactivity
Sections of glycemic hamster pancreas at 10 weeks. Purple 
chromogen deposition indicates immuno-reactivity with insulin. 
200X.
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Hamster Aortic Arch Lesion Development
Cross sections of hamster aortic arch at 20 weeks. N 
represents non-lipidemic/non-glycemic hamsters, G represents 
glycemic hamsters, L represents lipidemic hamsters and L + G 
represents lipidemic/glycemic hamsters. 200X.
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Hamster Aortic Arch MDA Immuno-reactivity
Cross sections of hamster aortic arch at 20 weeks. N represents 
non-lipidemic/non-glycemic hamsters, G represents glycemic 
hamsters, L represents lipidemic hamsters and L + G represents 
lipidemic/glycemic hamsters. Red chromogen deposition 
indicates immuno-reactivity with MDA. 200X.
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Hamster Aortic Arch LOX-1 Immuno-reactivity
Cross sections of hamster aortic arch at 20 weeks. N 
represents non-lipidemic/non-glycemic hamsters, G represents 
glycemic hamsters, L represents lipidemic hamsters and L + G 
represents lipidemic/glycemic hamsters. Red chromogen 
deposition indicates immuno-reactivity with LOX-1. 200X.
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N L G L+G
Treatment Group
b significantly increased over a. c significantly increased 
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b significantly increased over a. c significantly increased 


























O) 2000  






b b b b











































\  N| \  \  \  N N N No o o o o o oo w o io o in o^ CO CO CM CM T- T-
(-|p/6w) esoonio
142






























































o o s <o i o * m c m t - o
(l/\|n) sapixojedojpAn pjdn






























Correlation between total cholesterol and lipid 








O 1 r = 0.5033 
p = 0.0237
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Role of Oxidized LDL Receptors (LOX-1) in Atherogenesis in Normal and Diabetic Animals
All cage, pen or other animal identification records must include your IACUC Protocol #  as listed above.
The Institutional Animal Care and Use Committee has reviewed and approved the protocol submitted for this 
study under Category 3 on Page 3 of the "Application for Review of Animal Use or Instruction Protocol" - the 
research involves chronic maintenance of animals with a disease/functional deficit and/or procedures 
potentially inducing moderate pain, discomfort or distress which will be treated with appropriate 
anesthetics/analgesics.
Approval is granted for a period of three years from the approval date above. Continued approval throughout 
the three year period is contingent upon completion of annual reports on the use of animals. At the end of the 
three year approval period you may submit a new application and request for extension to continue this project. 
Requests for extension must be filed prior to the expiration of the original approval.
Please note: Use of animals in research and instruction is approved contingent upon participation in the UNH 
Occupational Health Program for persons handling animals. Participation is mandatory for all principal 
investigators and their affiliated personnel, employees of the University and students alike. A Medical History 
Questionnaire accompanies this approval; please copy and distribute to all listed project staff who have not 
completed this form already. Completed questionnaires should be sent to Dr. Gladi Porsche, UNH Health 
Sendees.
If you have any questions, please contact either Van Gould at 862-4629 or Julie Simpson at 862-2003.
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